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DNA-damage-induced apoptosis in stem and cancer cells
A
is work comprises analyses of cell fate decision-making in response to DNA
damage. DNA damage is a ubiquitous threat to genomic stability, and depending
on the type and extent of the damage, can lead to widespread changes in cell func-
tion as well as cell death. How apoptosis, or programmed cell death, is triggered
in damaged cells was studied in diﬀerent cell types for diﬀerent types of damage.
Cell fate decisions are the outcome of information processing in signaling net-
works. When cells are challenged by DNA damage, the p network plays an im-
portant role in regulating diverse responses, including DNA repair, cell cycle ar-
rest, senescence, and apoptosis. e functionof thepnetwork inhumanembry-
onic stem cells (hESCs) and their diﬀerentiated progeny was characterized. Unex-
pectedly, little distinction in the p response between hESCs and diﬀerentiated
cells was found. Instead, higher damage sensitivity in hESCs compared with dif-
ferentiated cells was discovered to be determined by mitochondrial priming.
Heterogeneity in cellular damage responses was further explored in cancer cells
in response to the chemotherapy drug cisplatin. p dynamics were analyzed in
single cells after cisplatin-inducedDNA damage. While half the population under-
went apoptosis and half survived, both apoptotic and surviving cells reached sim-
ilar levels of p. However, cells that entered apoptosis accumulated p faster
than cells that survived cisplatin treatment. Hence, a “dynamic threshold” model
for p-dependent apoptosis was proposed, suggesting the threshold level p
must reach to induce apoptosis increases with time. Computational modeling was
used to explore possible mechanisms by which faster p increase could lead to
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apoptosis.
A new ﬂow cytometry method to concurrently detect progression through
apoptosis simultaneously with cell cycle phase across a population of cells was
developed. is technique, using the vital dye DyeCycle Violet and the apoptotic
stain YOPRO, allows quick and easy assessment of apoptosis and cell cycle arrest
in multiple conditions.
Overall, this set of experiments and analyses demonstrates the importance of
signaling networks and their interactions in determining cell state and damage
sensitivity. Using systems biology approaches to study cellular decision-making
may contribute to scientiﬁc understanding and clinical impact.
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Yet, our problem is the living organization and therefore our in-
terest will not be in properties of components, but in processes
and relations between processes realized through components.
Humberto Maturana and Francisco Varela, 
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Introduction
L ,     , are not static objects.
ey exist in complex and constantly changing environments, and must respond
appropriately to a variety of internal and external stimuli. To survive in such
changing conditions, cells must detect signals and then process that information
to adapt their cellular state to the new condition, for instance by altering gene ex-
pression or metabolism. Hence, cells are able to sense and respond to beneﬁcial
changes in environment, such as availability of a nutrient, or deleterious changes,

such as starvation. e signaling networks responsible for cellular information
processing are composed of interacting proteins and genes that jointly coordinate
cellular functions.
Signaling networks respond to numerous cellular stresses, including DNA dam-
age. In the absence of a proper damage response, cellular proliferation without re-
pair of DNA strand breaks can lead to the detrimental accumulation ofmutations.
Mutations that facilitate deregulated proliferation or predispose cells to acquire
further mutations are often associated with the development of cancer. Hence,
cells protect themselves from genomic instability by activating the DNA damage
response, which ensures that the cell will stop dividing and initiate DNA repair.
In cases of signiﬁcant or irreparable damage, the DNA damage response will lead
the cell to undergo irreversible cell fates such as senescence (permanent cell cycle
arrest) or apoptosis (programmed cell death). us, determining the appropriate
response for the level and type of damage is critical.
. T     DNA 
e tumor suppressor p is a central protein in mammalian biological networks
that respond to stress. p is one of the most frequently mutated proteins in
human cancers, and somatic mutations in p have been found in half of human
tumors (Greenblatt et al., ). Moreover, in tumors that retain wild-type p,
mutations in p-associated pathways often render p inactive. Inheritance of
pmutations causes propensity to development of rare tumors in childhood and
predisposition to early-onset common cancers in adulthood. Such germline p
mutations deﬁne the condition known as Li-Fraumeni syndrome. Consistent with
p’s function as a barrier to tumor progression, restoration of wild-type p can

promote the regression of tumors in vivo (Ventura et al., , Xue et al., ).
For the above reasons, p is commonly known as the “guardian of the genome”
(Lane, ).
e p network is relatively well characterized (Figure .). Under basal con-
ditions, p is expressed at low levels, primarily due to a negative feedback loop
through the E ubiquitin ligase Mdm. p activates transcription of Mdm,
which negatively regulates p by targeting it for ubiquitination and degradation.
Upstream of p, damage-sensing kinases such as ataxia telengiectesia mutated
(ATM) and checkpoint kinase  (Chk) are activated by phosphorylation upon for-
mation of DNA double-strand breaks (DSBs) caused by gamma irradiation. Tran-
scription of the p gene remains constant; instead, active ATM-P and Chk-P
phosphorylate the p protein, leading to its stabilization and accumulation. Af-
ter DNA damage, p and Mdm show pulses. ese pulsatile dynamics were
originally characterized as damped oscillations from population-averaging stud-
ies, but were later shown to be pulses of ﬁxed amplitude and duration in single-cell
experiments. e negative feedback loop between p and its negative regulator
Mdm was found to be insuﬃcient for recurrent p pulses; rather, there is a sec-
ond negative feedback loop from p to the upstream signaling kinases via the
phosphatase Wip (Batchelor et al., , Geva-Zatorsky et al., ). Wip is a
transcriptional target of p and can dephosphorylate p as well as ATM-P and
Chk-P, shutting down their activity (Fujimoto et al., , Lu et al., , Shree-
ram et al., ). As a result of these feedbacks, p pulses after DSB induction
show excitability (Batchelor et al., , Loewer et al., ). Similar to an action
potential in a neuron, a pulse of p will complete its full excitation once acti-
vated, even if the stimulus is inhibited during the pulse. Furthermore, each pulse

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Figure 1.1: The p53 network. Schematic of the upstream and downstream inter-
actions involved in the p53 response to damage. For simplicity, not all known inter-
actions are shown; inhibitory arrows from ATM and ATR to Mdm2 and from Wip1 to
Chk1 have been omitted for clarity. Adapted from Alexander Loewer and Eric Batche-
lor.

of p has nearly uniform amplitude and duration independent of the dose of
damage, and it is the number of pulses that correlates with the damage dose (La-
hav et al., ). Based on these ﬁndings, our current understanding of post-DSB
p dynamics is that p behavior is more closely analogous to successively trig-
gered pulses rather than autonomous oscillations. is model is termed recurrent
initiation (Batchelor et al., ).
Diﬀerent types of damage can lead to diﬀerent patterns of p dynamics. As
mentioned, gamma irradiation leads to DSBs, activating ATM and a series of un-
damped pulses of p. In contrast, UV irradiation induces diﬀerent types of DNA
lesions, two classes of which are cyclobutane–pyrimidine dimers (CPDs) and –
photoproducts (–PPs, which are pyrimidine adducts) (Sinha and Häder, ).
Repair of these lesions via nucleotide excision repair and base excision repair tran-
siently produces single-stranded DNA. Single-stranded DNA (ssDNA) induced by
UV irradiation leads to the activation of the ataxia telangiectasia and Rad re-
lated (ATR) protein kinase and a single dose-dependent p pulse (Batchelor et al.,
). is single p pulse, unlike the pulses triggered by DSBs, is not excitable,
as inhibition of ATR shortly following UV irradiation attenuates the accumulation
of p, suggesting that the p pulse is dependent on continuous ATR activation.
Excitability of the p response to DSBs and not to ssDNA was shown to be de-
pendent on several diﬀerences in two pathways, including feedback from Wip
on ATM and not ATR, and rapid degradation of Mdm upon its phosphorylation
by ATM. Hence, network architecture contributes to a graded-amplitude p re-
sponse toUV irradiation that is distinct from the pulsatile p response to gamma
irradiation (Batchelor et al., ). at the dynamics of p are dependent on
the stimulus and that diﬀerent stimuli – gamma versus UV irradiation – activate

distinct targets of p (Zhao et al., ), suggest that p dynamics could be
important for the regulation of cell fate decisions.
Of clinical relevance, many drugs used to treat cancers cause DNA damage but
in functionally diﬀerent ways from gamma or UV irradiation. For instance, the
chemotherapy drug cisplatin has been used to treat solid tumors, including tes-
ticular and ovarian cancers (Kelland, ). A platinum complex, it forms both
interstrand and intrastrand DNA crosslinks. eDNA adducts caused by cisplatin
are detected by various DNA damage-sensing and repair pathways (Helleday et al.,
), and also lead to a p response. e dynamics of p and subsequent cel-
lular responses following cisplatin treatment will be discussed in Chapter .
One possible response to DNA damage is transient cell cycle arrest and DNA
repair. In this case, cells survive, repair DNA breaks induced by the damage, and
then re-enter the cell cycle. p is an important mediator of cell cycle arrest and
DNA repair and activates the transcription of genes involved in both processes.
For instance, CDKNA, SFN, and CDCC are p target genes involved in cell
cycle arrest, and DDB, GADDA, and XPC are p targets associated with re-
pair (Purvis et al., , Riley et al., ). In single cells, pulses of p triggered
by DNA DSBs have been observed to correlate with the number of DSBs induced
(Loewer et al., ). Higher levels of damage lead to more p pulses, suggest-
ing that the extent of DNA repair is monitored and that persistent damage will
continue to trigger p.
p also has target genes involved in permanent cell cycle arrest, termed senes-
cence. One example is the CDKNA gene, encoding the protein p, which has
important roles in both temporary arrest and senescence. e cell fate decision be-
tween arrest and senescence is dependent on p dynamics after damage. When

pulses of p after gamma irradiation were altered to create a sustained level of
p activation, the expression of downstream target genes of p changed (Purvis
et al., ). Notably, p levels were signiﬁcantly higher in sustained p condi-
tions. Consistent with that observation, sustained p led to a greater fraction of
cells that underwent senescence, instead of transient cell cycle arrest and re-entry
into the cell cycle (Purvis et al., ). ese ﬁndings suggest that p dynamics
might encode information to speciﬁcally select a particular cell fate.
. T     
emost acute terminal response to DNA damage is apoptosis. Comprising mul-
tiple stages, apoptosis is a highly stereotyped mode of cell death (Elmore, ).
It plays an important role not only in defense against damage but also in devel-
opment, aging, and homeostasis, and is considered a type of “programmed” cell
death. In contrast to necrosis, or uncontrolled cell death that is often the result
of injury or trauma, apoptosis does not trigger inﬂammation and an immune re-
sponse. It is characterized morphologically by cell shrinkage, chromatin conden-
sation, and nuclear fragmentation (Taylor et al., ). e plasmamembrane ex-
hibits “blebbing” – formation of bulges and protrusions – and portions of the cell
are encapsulated into membrane-bound vesicles named apoptotic bodies, which
contain cytoplasm, organelles, and nuclear fragments. Apoptotic bodies are rec-
ognized and engulfed by phagocytes such as macrophages, and hence apoptosis
does not generate an immune response (Kerr et al., ).
Unlike the extrinsic apoptotic pathway, which occurs via the binding of ex-
tracellular death ligands to transmembrane receptors, the intrinsic pathway is
non-receptor-mediated and relies on intracellular signaling, for instance the DNA

damage response. Both pathways converge upon the mitochondria, the sites of
apoptotic initiation. Mitochondrial outer membrane permeabilization (MOMP)
is one of the ﬁrst steps in apoptosis and occurs when Bax (Bcl--associated X
protein) and/or Bak (Bcl--antogonist/killer-) become activated via conforma-
tional changes and oligomerize at the mitochondrial outer membrane (Dewson
and Kluck, ). Following MOMP, multiple events occur, including the release
of cytochrome c from the mitochondrial intermembrane space into the cyto-
plasm, where it can trigger the formation of the apoptosome. e apoptosome
is a large protein complex assembled from cytochrome c and Apaf- (apoptotic
protease-activating factor-), which recruits pro-caspase- and results in the
allosteric activation of caspase- (Acehan et al., ).
Caspases (cysteine aspartic acid-speciﬁc proteases) are a family of highly
speciﬁc proteases, subdivided into initiators and eﬀectors (Nicholson, ).
Caspase-, for instance, is an initiator caspase and can auto-activate and activate
other caspases through proteolytic processing. us, active caspase- propa-
gates a cascade of downstream caspase activation. Caspase-, -, and - are the
eﬀector caspases responsible for cleavage of the majority of substrates during
apoptosis, including cytoskeletal proteins such as actins, tubulins, and associated
proteins (Taylor et al., ). Caspases also activate endonucleases that medi-
ate DNA fragmentation and chromatin condensation. A multitude of proteins
involved in various cellular functions are also attacked by caspases, including
poly(ADP-ribose) polymerase (PARP) (Duriez and Shah, ). PARP cleavage
serves as a hallmark of apoptosis and caspase activation, and its presence is often
used experimentally for detection of apoptosis.
In addition to the identiﬁcation of cleavage products of caspases, there are

many other methods to detect apoptosis. Caspase activation can be assayed by
Western blot or other antibody-based techniques. Other features of apoptosis
that serve to identify it experimentally include DNA fragmentation, which can
be detected by the TUNEL (Terminal dUTP Nick End-Labeling) method (Gavrieli
et al., , Kressel and Groscurth, ). Membrane-based assays take ad-
vantage of biochemical properties of apoptotic cells, including the movement
of phosphatidylserine from the inner leaﬂet of the plasma membrane, where it
resides in healthy cells, to the outer membrane leaﬂet as a signal for phagocytosis.
When phosphatidylserine is thus exposed, it can be detected by Annexin V, a
recombinant phosphatidylserine-binding protein (Koopman et al., ). Assays
to detect apoptosis will be discussed in more detail in the Appendix.
Control and regulation of apoptotic mitochondrial permeabilization are the re-
sponsibility of the Bcl- family of proteins (Figure .). ese proteins, deﬁned
by conserved sequence motifs known as Bcl- homology domains (BH to BH),
include both pro-apoptotic and pro-survival members (Youle and Strasser, ).
Bcl- itself and its close relatives Bcl-xL, Bcl-w, and Mcl- contain all four BH do-
mains and are anti-apoptotic. e pro-apoptotic proteins of this family can be
divided into the Bax-like subfamily, including Bax, Bak, and Bok, which have BH,
BH, and BH but lack BH, and the BH-only subfamily, which have homology
only within the BH motif, which is essential for pro-death function. Bax and
Bak as mentioned above are required for triggering MOMP, and their activation,
allosteric conformational change, and oligomerization are induced by the “activa-
tor” BH-only proteins Bid andBim (Chipuk et al., ). eother BH-only pro-
teins, including Bad, Puma, and Noxa among others, are termed “sensitizers,” as
they do not induce activation of Bax/Bak directly. Instead, they promote apopto-

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Figure 1.2: The Bcl-2 family of pro-apoptotic and anti-apoptotic proteins. In
response to damage, activators activate eﬀectors, causing mitochondrial permeabi-
lization and commitment to death. Anti-apoptotic proteins sequester activators, and
sensitizers act as selective inhibitors of anti-apoptotic proteins. Pro-apoptotic proteins
are shown in ovals and anti-apoptotic proteins in rectangles. Puma is colored dif-
ferently to indicate that it may also act as an activator (Kim et al., 2006). Adapted
from Deng et al., 2007.

sis by occupying and inhibiting the anti-apoptotic proteins, freeing the activators.
ere is evidence that Puma can also function as an activator (Kim et al., ).
In short, anti-apoptotic Bcl- family members bind and sequester pro-apoptotic
BH-only proteins and also block activation of Bax and Bak. In response to dam-
age, the stabilization, increased transcription, or modiﬁcation of BH-only pro-
teins counteract and overwhelm the reserve of anti-apoptotic proteins, leading to
Bax and Bak activation and MOMP (Huang and Strasser, ).
At least twomajor roles for p in regulating cell-intrinsic apoptosis have been
described. p mediates the transcription of multiple target genes whose pro-
tein products are known to be involved in apoptosis, such as Puma, Noxa, Bax,
and Apaf (Oda et al., a, Riley et al., ). After damage, synthesis of these
pro-apoptotic proteins can be upregulated dependent on transcription by p. In
addition, multiple studies show that p can promote apoptosis by directly in-
teracting with mitochondrial proteins (Green and Kroemer, , Speidel, ).
p was shown to bind and antagonize anti-apoptotic proteins such as Bcl- and
Bcl-xL, resulting in MOMP and cytochrome c release (Mihara et al., , Tomita
et al., ). Other studies have demonstrated that p can directly activate Bax
and also release other pro-apoptotic proteins from Bcl-xL (Chipuk et al., ).
is role of p as a direct activator of Bax could be complemented by joint func-
tion of p’s transcriptional target Puma as a sensitizer, relieving p from bind-
ingwith Bcl-xL (Chipuk et al., ). p function as an activatormay also pertain
to Bak as well as Bax, as p has been observed to disrupt Bak sequestration by
Mcl-, leading to oligomerization and activation of Bak (Leu et al., , Pietsch
et al., ). p may also act as a sensitizer, as Tet-inducible p can displace
the BH-only activator Bim from anti-apoptotic proteins including Mcl-, Bcl-,

and Bcl-xL (Han et al., ). Taken together, it is clear that p potentially
has multiple protein-protein interactions with pro-apoptotic and anti-apoptotic
Bcl- family members. Hence, p exhibits both transcription-dependent and
transcription-independent activity in promoting apoptosis.
. T DNA     
Diﬀerent cell types favor diﬀerent responses to cellular stress, ranging from cell
cycle arrest and DNA repair to senescence or apoptosis. Human embryonic stem
cells (hESCs) are known to be acutely sensitive to DNA damage. As an important
cell population that gives rise to all tissues in the body, hESCs are expected to
undergo apoptosis after damage to prevent damaged cells from compromising the
genomic integrity of the organism. Conversely, adult stem cells may need to be
resistant to DNA damage, as unchecked apoptosis might compromise tissue and
organ structure. Hence stem cells are caught between two opposing needs: on one
hand they should block the propagation ofmutations to their progeny cells, yet on
the other hand they have a responsibility to preserve existing tissue organization.
Multiple studies have shown that hESCs have higher rates of apoptosis after
damage than diﬀerentiated cells (Filion et al., , Grandela et al., , Qin
et al., ), yet this phenomenon is still incompletely understood. Several dis-
tinct mechanisms have been proposed to explain how the regulatory networks
that control apoptosis might have unique functions in hESCs (Figure .). Not
only is p well-known regulator of cell fate decisions in somatic cells (Vousden
and Lane, ), it is also induced after various types of damage in hESCs. Fur-
thermore, apoptosis of hESCs was shown to be dependent on p (Grandela et al.,
, Qin et al., ). However, multiple studies suggest diverse roles for p in

promoting apoptosis in hESCs. Consistent with its transcription factor activity,
p was found to translocate to the nucleus of hESCs upon treatment with etopo-
side, an inhibitor of topoisomerase II (Grandela et al., ). In contrast, in hESCs
treated with UV irradiation p does not transcribe target genes but instead ac-
tivates apoptosis through the mitochondrial pathway (Qin et al., ). More re-
cently, the pro-apoptotic protein Bax, a transcriptional target of p, was shown
to be a major activator of rapid apoptosis in hESCs. hESCs, unlike diﬀerentiated
cells, maintain Bax in its active conformation at the Golgi apparatus (Dumitru
et al., ). Upon DNA damage caused by etoposide, Bax rapidly localizes to the
mitochondria and initiates apoptosis. While Bax translocation is also observed to
be dependent on p, the exact mechanism generating the translocation remains
unclear. Interestingly, the basal level of active Bax varies substantially among dif-
ferent hESC lines, and is not detectable in at least one line (H) (Dumitru et al.,
). Nonetheless, H cells show the typical hESC sensitivity to DNA damage,
suggesting that apoptosis can also be induced by other mechanisms (Liu et al.,
).
InChapter , wewill thoroughly discuss our investigations onDNAdamage-induced
apoptosis in hESCs in comparison with their diﬀerentiated progeny (Liu et al.,
). Brieﬂy, activation of apoptosis was dependent on p, consistent with
previous ﬁndings. e transcription of apoptotic target genes of p, including
PUMA, APAF, and FAS, was induced after damage in hESCs. However, these
same genes were also upregulated in diﬀerentiated cells, suggesting that p
transcriptional activity does not distinguish hESCs from diﬀerentiated cells. p
was observed in the cytoplasm of hESCs, and a cytoplasm-conﬁned mutant p
conﬁrmed that cytoplasmic p alone is able to induce apoptosis. However, cy-
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Figure 1.3: Multiple pathways contribute to hESC sensitivity to DNA damage.
1) The tumor suppressor protein p53 acts as a transcription factor, activating tran-
scription of pro-apoptotic target genes. The pro-apoptotic protein products proceed
to induce apoptosis at the mitochondria. 2) p53 also has transcription-independent
direct interactions with pro-apoptotic and anti-apoptotic proteins in the cyto-
plasm that promote apoptosis. 3) High mitochondrial priming, implying a high ra-
tio of pro-apoptotic to anti-apoptotic proteins, maintains hESCs close to the apop-
totic threshold. 4) The apoptotic protein Bax is localized in its active conforma-
tion at the Golgi apparatus in some hESCs, poised to induce rapid apoptosis after
damage-induced translocation to the mitochondria.

toplasmic p was also present in diﬀerentiated cells. ese results led to the
hypothesis that while p signaling appeared similar in hESCs and diﬀerentiated
cells, the internal environment of the two cell types diﬀers and explains their
diﬀerential sensitivity to DNA damage.
Recent studies have shown that sensitivity to DNA damaging drugs could be
predicted by a cellular property termed mitochondrial priming. Mitochondrial
priming is determined by the balance between pro-apoptotic and anti-apoptotic
Bcl- family proteins (Certo et al., ). As described above, the functions of the
anti-apoptotic proteins Bcl-, Bcl-xL, Mcl-, etc. are to antagonize Bak and Bax
activation and oligomerization, whereas pro-apoptotic BH-only proteins pro-
mote Bak and Bax activation, in many cases by inhibiting the anti-apoptotic pro-
teins. e relative abundance and impact of the pro-apoptotic and anti-apoptotic
proteins can be measured by BH proﬁling (Ni Chonghaile et al., ). BH
proﬁling quantiﬁes the magnitude of mitochondrial depolarization, representing
MOMP, upon exposure to a panel of pro-apoptotic, promiscuously interacting
BH peptides. Greater sensitivity to the BH peptides indicates closer proximity
to the apoptotic threshold, as MOMP can be initiated more readily. Moreover,
some BH-only proteins (for example, Bid and Bim) interact with eﬀectively all
anti-apoptotic Bcl- proteins, whereas others (for example, Noxa) interact only
with certain Bcl--family members. Due to diﬀerential binding of anti-apoptotic
proteins to the diﬀerent BH-only proteins, BH proﬁling can be used to probe
which anti-apoptotic proteins contribute more or less to blocking apoptosis in
a particular cell line or tissue (Deng et al., ). Consistent with their higher
damage sensitivity, hESCs exhibited higher mitochondrial priming for all BH
peptides than their diﬀerentiated progeny and hence were closer to the apoptotic

threshold. We concluded that in diﬀerent cellular environments, the function of
the same signaling pathway - the p-regulated DNA damage response - produces
a dramatic diﬀerence in cell fate between hESCs and diﬀerentiated cells.
Altogether, the problem of howmultiple networks interact and sum together to
produce the appropriate cellular response to a given stimulus is complex and not
fully understood. is thesis discusses some processes known to contribute to the
DNA damage response in several cell types. In particular, the p protein plays
a prominent role in the regulation of downstream pathways leading to diﬀerent
cell fates, including apoptosis. In Chapter , we discuss our investigation of the
function of p in hESCs. We show that while DNA-damage-induced apoptosis is
p-dependent, mitochondrial priming determines hESCs’ sensitivity to damage.
In Chapter , we analyze quantiﬁable characteristics of p behavior that inﬂu-
ence the cell fate decision of colon cancer cells in response to the chemotherapy
drug cisplatin. Finally, we include an Appendix describing the ﬂow cytometry as-
say we developed to measure the eﬀects of a drug or other perturbation on both
cell cycle phase and apoptosis. Together, this work presents examples of how reg-
ulatory networks interact to commit to a particular cell fate. Using a variety of
methods, from population to single cell assays, we develop greater insight into
individual molecular mechanisms regulating cell fate decisions, as well as the in-
terconnected relationships among the mechanisms.

Hewhose eye happens to look down into the yawning abyss be-
comes dizzy.
Søren Kierkegaard
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High mitochondrial priming sensitizes hESCs
to DNA damage
O         DNA  - in-
cluding DNA repair, cell cycle arrest, senescence, and apoptosis - human embry-
onic stem cells (hESCs) primarily undergo apoptosis (Momcilovic et al., ,Wil-
son et al., ). hESCs are able to self-renew indeﬁnitely and can diﬀerentiate
into all cell lineages in the body, making it particularly important that they main-

tain genomic integrity. eir high sensitivity to DNA damage and ability to dif-
ferentiate make them a good model system for studying the regulatory networks
that control apoptosis and how they diﬀer between hESCs and their diﬀerentiated
progeny.
One important protein controlling cell fate decisions in response to DNA dam-
age is the tumor suppressor protein p (Vogelstein et al., , Vousden and
Lane, ). p was previously shown to be induced in response to DNA dam-
age in hESCs, primarily triggering apoptosis (Filion et al., , Grandela et al.,
, Qin et al., ). In somatic cells, p is known to contribute to cell death
through two primary mechanisms. First, nuclear p activates the transcription
of pro-apoptotic proteins, such as PUMA, Bax, and NOXA (Villunger et al., ).
Second, cytoplasmic p directly interacts with mitochondrial proteins, acting ei-
ther as a direct activator of Bak and/or Bax oligomerization, or as a sensitizer,
by sequestering anti-apoptotic proteins (Green and Kroemer, ). In hESCs,
there is evidence that p triggers apoptosis exclusively through the mitochon-
drial pathway after UV irradiation (Qin et al., ). However, other work showed
that p not only associates with mitochondria but also translocates to the nu-
cleus in response to DNA breaks caused by the topoisomerase II-poison etoposide,
suggesting that induction of apoptosis by p involves a transcription dependent
pathway (Grandela et al., ). Additionally, the genome-wide transcriptome
of hESCs after gamma irradiation revealed altered gene expression of primarily
p-dependent, pro-apoptotic transcripts (Sokolov et al., ).
e cellular responses of diﬀerentiated cells to DNA damage diﬀer widely de-
pending on the tissue of origin. For example, tissues vary drastically in their sur-
vival ability after irradiation: some tissues, including those comprising bone mar-

row, small intestine, thymus, and spleen, are acutely aﬀected by even low doses
of radiation, while tissues from kidney, heart, liver, and lung are relatively resis-
tant (Gudkov and Komarova, ). While it is thought that sensitivity to DNA
damage tends to be characteristic of highly proliferating cells, some rapidly divid-
ing tumors are resistant to chemotherapy while other slowly dividing tumors are
chemosensitive, suggesting that additional factors aﬀect the cellular damage re-
sponse (Gudkov and Komarova, ). Distinct p expression and activity in
cells from diﬀerent tissues can be a factor contributing to diﬀerential tissue sen-
sitivity to DNA damage (Komarova, ). In addition, recent studies have found
that cells’ relative mitochondrial priming aﬀects their sensitivity to DNA dam-
aging drugs (Certo et al., , Ni Chonghaile et al., , Vo et al., ). Mi-
tochondrial priming denotes the intrinsic potential of cells to undergo apoptosis
due to the balance of pro- and anti-apoptotic Bcl- family proteins at the mito-
chondria, and can be assessed by BH proﬁling (Ni Chonghaile et al., ). is
assay measures mitochondrial outer membrane permeabilization (MOMP) after
mitochondria are exposed to pro-apoptotic promiscuously interacting BH pep-
tides. Highermitochondrial priming determined byBHproﬁling has been shown
to correlate with clinical response in several cancers (Ni Chonghaile et al., )
as well as increased chemosensitivity (Vo et al., ).
Here we determined the origin of the sensitivity of hESCs to DNA damage com-
pared with their diﬀerentiated progeny. Speciﬁcally we investigated whether the
p pathway is diﬀerentially induced in hESCs and diﬀerentiated cells or whether
other intrinsic cellular properties can explain the diﬀerence in sensitivity. We
found that DNA damage rapidly induced p-dependent apoptosis in hESCs. p
target genes were also induced; however, inhibition of p’s transcriptional activ-
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Figure 2.1: DNA damage leads to rapid apoptosis in undiﬀerentiated hESCs
but not in diﬀerentiated cells. A. Immunoblot of c-PARP and Oct4 in hESCs and
diﬀerentiated cells treated with 100 ng/ml of NCS. B. Immunoblot of c-PARP and
Oct4 of cells diﬀerentiated with  µ RA for 0, 1, 2, 3, and 4 days, before and after
NCS treatment for 3 hours. C. Immunoblot of c-PARP and Oct4 in hESCs trans-
fected with scramble or Oct4 siRNA and treated with NCS.
ity or expression of exclusively cytoplasmic p did not prevent apoptosis, sug-
gesting that p’s cytoplasmic function is the main contributor to apoptosis of
hESCs. p was also induced in diﬀerentiated cells. Its localization and function
did not diﬀer between hESCs and diﬀerentiated cells. Instead, we found that dif-
ferential mitochondrial priming, measured by BH proﬁling, determined the sen-
sitivity of hESCs to DNA damage. hESCs showed high mitochondrial priming rel-
ative to their diﬀerentiated progeny. Increasing the low priming of diﬀerentiated
cells increased their sensitivity to DNA damage and led to apoptosis.

. DNA     -  
ESC     
We ﬁrst characterized the response of hESCs to DNA damage and compared their
behavior with that of diﬀerentiated cells from the same background. DNAdamage
was induced using the radiomimetic drug neocarzinostatin (NCS), which creates
double-stranded DNA breaks (DSBs) within ﬁve minutes following its addition
to cell culture medium (Shiloh et al., ). Cells were diﬀerentiated with  µ
retinoic acid (RA) for  days (Andrews, ), and diﬀerentiation was conﬁrmed
using an antibody against Oct, one of the key pluripotency genes in hESCs (Niwa
et al., ). Induction of apoptosis was measured using an antibody against the
-kDa fragment of cleaved PARP (c-PARP), which is cleaved during apoptosis by
caspase-. We found that hESCs accumulated c-PARP within  hours after DNA
damage. In contrast, diﬀerentiated cells exhibited no c-PARP (Figure .A). Treat-
ment of hESCs with RA for shorter periods allowed us to investigate cells in the
process of diﬀerentiation. Weobserved that decrease inOct duringRA treatment
was correlated with reduction of c-PARP after damage (Figure .B). We further
demonstrated the strong connection betweenpluripotency and induction of apop-
tosis by silencing Oct. Oct knockdown cells show a drastic reduction in c-PARP
levels after damage in comparison with hESCs treated with scramble siRNA (Fig-
ure .C). Sensitivity to DNA damage was conﬁrmed in two additional hESC lines
(Figure .A,B), suggesting that the diﬀerential sensitivity between stem and dif-
ferentiated cells is not limited to one speciﬁc line. Furthermore, the higher induc-
tion of c-PARP in hESCs compared with their diﬀerentiated progeny was consis-
tently reproduced in response to additional DNA damage-inducing agents, includ-

0 1.5 3 4.5
CHB8 CHB8 Differentiated
actin
actin
c-PARP c-PARP
Oct4
Oct4
p53
actin
c-PARP
Oct4
p53
p53
0 1.5 3 4.5 0 1 2 3 4 5 0 1 2 3 4 5
HUES9 HUES9 Differentiated A B
C
- - - - -+ + + + + RA differentiation
unt
rea
ted
NC
S
UVγ-IR eto
pos
ide
Time (h) Time (h)
Figure 2.2: DNA damage leads to rapid apoptosis in undiﬀerentiated hESCs
but not in diﬀerentiated cells. A. Immunoblot of c-PARP, p53, and Oct4 in CHB8
hESCs and CHB8 cells diﬀerentiated with  µ RA for 4 days, treated with 100 ng/ml
of NCS. B. Immunoblot of c-PARP, p53, and Oct4 in HUES9 hESCs and HUES9 cells
diﬀerentiated with RA for 4 days, treated with NCS. C. Immunoblot of c-PARP, p53,
and Oct4 in hESCs and diﬀerentiated cells, untreated or treated for 3 h with NCS,
2.5 Gy -irradiation,  µ etoposide, or 10 J/m UV.

ing -irradiation, UV radiation and etoposide (Figure .C).
Annexin V measurements conﬁrmed that hESCs, but not diﬀerentiated cells,
undergo apoptotic death after DNA damage (Figure .A). Consistently, cell cycle
analysis showed that the sub-G fraction of the population, which represents dead
cells, increases rapidly in undiﬀerentiated cells (Figure .B). Over  of cells
died within  hours after damage. In contrast, the sub-G fraction of the diﬀeren-
tiated cells remained low following DNA damage. We noticed that a small fraction
of hESCs survived the damage. To determine whether these were resistant stem
cells, or spontaneously diﬀerentiated cells, we monitored the levels of Oct and
c-PARP in the surviving cells  hours after damage. We found that the remaining
cells were no longer Oct-positive (Figure .C), suggesting that they had already
diﬀerentiated in culture or in response to the damage. ese surviving diﬀerenti-
ated cells were also c-PARP-negative, supporting pluripotency as a determinant
of sensitivity to damage. In agreement, immunoﬂuorescence (IF) experiments
revealed that in a colony comprising both undiﬀerentiated (Oct-positive) and
spontaneously diﬀerentiated (Oct-negative) cells, c-PARP was only detectable in
the undiﬀerentiated cells (Figure .D). is diﬀerence in sensitivity was not due
to diﬀerent extents of DNA damage incurred by NCS since the levels of -HAX,
the canonical marker for double strand breaks (Löbrich et al., ), were com-
parable between undiﬀerentiated and diﬀerentiated cells (Figure .). Taken to-
gether, these results show that hESCs, unlike their diﬀerentiated progeny, re-
spond toDNAdamage by rapidly undergoing apoptosis. is highly sensitive dam-
age response is linked to pluripotency.
We next determined whether p plays a role in the induction of apoptosis in
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Figure 2.3: Conﬁrmation of apoptotic cell death in hESCs but not diﬀerenti-
ated cells. (A). Plots of DAPI incorporation (measuring cell permeabilization) versus
Annexin V staining, of hESCs (top row) and diﬀerentiated cells (bottom row) treated
with NCS for 0, 2, and 4 hours. (B). DNA content (propidium iodide incorporation)
measured by ﬂow cytometry of hESCs and diﬀerentiated cells, treated with NCS. The
percentage of cells in the sub-G1 fraction is marked. (C). Immunoblot of c-PARP and
Oct4 in hESCs at later time points after NCS treatment. (D). Immunoﬂuorescence
images of an hESC colony co-stained with DAPI and antibodies against Oct4 and
c-PARP, ﬁxed 2.5 hours after damage with NCS.
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Figure 2.4: Undiﬀerentiated and diﬀerentiated cells experience similar levels
of NCS-induced DNA damage. Immunoﬂuorescence images of hESCs and diﬀer-
entiated cells before and 15min after treatment with NCS. Cells were co-stained with
DAPI and antibodies against Oct4 and -H2AX.
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hESCs in response to DNA damage. p levels were induced in hESCs following
DSBs (Figure .A). Knocking down p using siRNA abrogated the c-PARP re-
sponse (Figure .A). In addition, cultures treated with siRNA against p did not
show the colony shrinkage or the ﬂoating cells observed in damaged hESC cul-
tures (Figure .B).is shows that p is required for activation of the apoptotic
pathway in hESCs in response to DNA damage. To determine whether apoptosis
in hESCs can be triggered solely by elevation of p and independently of DNA
damage we treated cells with Nutlin-a. Nutlin-a is a small molecule that in-
hibits the binding of Mdm, a major negative regulator of p, to p, thereby
increasing p stability (Vassilev et al., ). Nutlin-a led to accumulation of
p and c-PARP to levels comparable to those observed in response to DNA dam-
age (Figure .C). e ability of Nutlin-a to trigger apoptosis in hESCs suggests
that stabilization of p is suﬃcient to induce apoptosis without requiring addi-
tional damage-dependent post-translationalmodiﬁcations. To further strengthen
the dependency of cell death on pwe used a short hairpin RNA (shRNA) against
p that is stably integrated into hESCs via lentiviral infection. Cells carrying the
pshRNA lost induction of p and showed no c-PARP after DNA damage and
Nutlin-a treatments (Figure .C). Similar results were obtained when we used
a diﬀerent hESC line, HUES, and compared c-PARP levels after NCS treatment
between wild-type and p-/- cells (Figure .D).
p activates transcription of pro-apoptotic genes in both hESCs and diﬀer-
entiated cells. In somatic cells, p acts as a transcription factor activating many
target genes, including pro-apoptotic genes (Riley et al., ). We asked whether
p also activates transcription of pro-apoptotic genes in damaged hESCs, poten-
tially contributing to their death in response to DNA damage. We used qRT-PCR
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Figure 2.6: p53 transcriptional activity is induced after DNA damage. (A).
Relative mRNA expression of pro-apoptotic p53 target genes in hESCs treated
with 100 ng/ml NCS, as measured by RT-qPCR. mRNA levels were normalized
to GAPDH. (B). Relative PUMA mRNA expression after treatment with NCS in
hESCs transfected with scramble or p53 siRNA. (C). Immunoblots of c-PARP, p53,
PUMA, and Oct4 after treatment with NCS in hESCs transfected with scramble or
p53 siRNA. Data are represented as mean +/- SD.
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and diﬀerentiated cells. (A). Relative mRNA expression of pro-apoptotic p53 target
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of c-PARP, p53, PUMA, and Oct4 in hESCs and diﬀerentiated cells, damaged with
NCS. Data are represented as mean +/- SD.
to measure mRNA levels in hESCS of known p transcriptional targets involved
in apoptosis (Müller et al., , Nakano and Vousden, , Oda et al., a,b,
Riley et al., , Robles et al., , ornborrow et al., ). Two genes (BAX
and TPAIP) showed almost no induction (Figure .A). ree genes (FAS,
APAF, and NOXA) showed between - to -fold induction  hours after damage.
Notably, PUMA, a gene encoding a pro-apoptotic BH-only protein that inhibits
anti-apoptotic proteins (Chipuk et al., ), showed more than -fold induction
in mRNA level following DNA damage. PUMA mRNA and protein levels were
signiﬁcantly reduced in cells silenced for p suggesting that activation of PUMA
following DNA damage is p-dependent (Figure .B,C).

Why do diﬀerentiated cells, which originated from the stem cell population,
show such a remarkable diﬀerence in their sensitivity to DNA damage? One pos-
sibility is that p does not activate transcription of pro-apoptotic genes in dif-
ferentiated cells. We compared mRNA levels of three pro-apoptotic p target
genes (PUMA, APAF, and FAS) between undiﬀerentiated and diﬀerentiated cells.
We found that these pro-apoptotic genes were induced in both undiﬀerentiated
and diﬀerentiated cells (Figure .A). In the case of APAF and FAS, mRNA lev-
els in diﬀerentiated cells even exceeded those in undiﬀerentiated cells. Moreover,
PUMA protein levels in diﬀerentiated cells reached comparable levels to those in
undiﬀerentiated cells, though the accumulation was slightly delayed in diﬀerenti-
ated cells (Figure .B). Taken together, these results show that p activates the
transcription of pro-apoptotic genes in both diﬀerentiated and undiﬀerentiated
cells. erefore, p’s transcriptional activity cannot explain the high sensitivity
of hESCs to DNA damage compared with diﬀerentiated cells.
. C      ESC
It has been shown that in addition to acting as a transcription factor, p can also
activate apoptosis through other mechanisms, for example by interacting with
mitochondrial proteins in the cytoplasm (Green and Kroemer, ). To deter-
mine whether such transcription-independentmechanisms contribute to apopto-
sis in hESCs we used the RNA polymerase-II poison -amanitin to inhibit tran-
scription during the DNA damage response. Surprisingly we found that hESCs
still activated apoptosis after DNA damage (Figure .A) even when p target
genes were not induced (Figure .B). is apoptosis was p-dependent, since
the psh hESCs did not activate c-PARP following damage and -amanitin treat-
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Figure 2.8: p53-induced apoptosis occurs even during inhibition of tran-
scriptional activity. (A). Immunoblot of c-PARP, p53, and Oct4 in hESCs and a
p53shRNA hESC line after 3 hours of 100 ng/ml NCS and/or 4 hours of  µg/ml
-amanitin treatment (1 hour pre-treatment when combined with NCS). (B). Rel-
ative Mdm2, PUMA, and NOXA mRNA expression of hESCs after 3 hours of NCS
and/or 4 hours of -amanitin treatment (1 hour pre-treatment when combined with
NCS). Data are represented as mean +/- SD. (C). p53 and DAPI immunoﬂuores-
cence images of hESCs ﬁxed at the indicated times after treatment with NCS. (D).
Immunoblot of p53 and c-PARP in the nuclear and cytoplasmic fractions of hESCs.
Cells were undamaged or damaged with NCS for 3 hours. Histone H4 and the tran-
scription factor Rb serve as nuclear markers, and tubulin as a cytoplasmic marker.
N = nuclear, C = cytoplasmic.
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ment (Figure .A). ese results show that even though p target genes are
upregulated in damaged hESCs, p transcriptional activity is not the main con-
tributor to the rapid apoptosis seen in these cells. We therefore checked whether
the cytoplasmic activity of p contributes to the apoptotic response in hESCs.
Using IF to probe the localization of p in damaged hESCs, we found that p
appeared primarily nuclear (Figures .D and .C). However, by separating cell
lysates into nuclear and cytoplasmic fractions, we found that a fraction of p
(about ) resided in the cytoplasm following DNA damage (Figure .D).ese
low levels of cytoplasmic p may be below the detection threshold of IF. To de-
termine whether cytoplasmic p can activate apoptosis in hESCs, we expressed
a mutant form of p conﬁned to the cytoplasm and tested its ability to activate
apoptosis. p contains a bipartite nuclear localization signal (NLS), part of which
includes Lys and Arg. e two amino acid substitutions KA and RA
cause p to be excluded from the nucleus (O’Keefe et al., ). We cloned the
KA and RA mutant p and fused it with an mVenus ﬂuorescent tag. Us-
ing lentiviral infection, we introduced this mutant p (cytop) into hESCs ex-
pressing pshRNA. Cytop contains synonymous substitutions that render it
resistant to shRNA knockdown. Cytop was exclusively expressed in the cyto-
plasm (Figure E) and showed no transcriptional activity (Figure F), in contrast
to a wild-type p-mVenus (wtp). We found that cells expressing cytop suc-
cessfully induced c-PARP after damage (Figure G). ese results show that cy-
toplasmic p contributes to the activation of apoptosis in hESCs. e levels of
c-PARP were lower in cells expressing cytop in comparison to cells expressing
wtp. is may result from reduced cytoplasmic function or misfolding due to
the inserted mutations.
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Figure 2.9: Residual cytoplasmic p53 is active in contributing to apopto-
sis in hESCs. (A). Phase and ﬂuorescent images of p53shRNA hESC lines with
re-introduced p53-mVenus (wtp53) and p53K305A,R306A-mVenus (cytop53) after
3 hours of damage with NCS. These cells were then collected for the immunoblots
in (C). (B). Relative PUMA mRNA expression in parental hESCs (wt), p53shRNA
hESCs (p53sh), and p53shRNA hESC lines with re-introduced p53-mVenus (wtp53)
and p53K305A,R306A-mVenus (cytop53) before and after treatment with NCS. Data
are represented as mean +/- SD. (C). Immunoblot of p53-Venus, p53, c-PARP, and
Oct4 in parental hESCs (wt), p53shRNA hESCs (p53sh), and p53shRNA hESC lines
with re-introduced p53-mVenus (wtp53) and p53K305A,R306A-mVenus (cytop53).
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. ESC,   ,    -
    
Since p’s transcriptional activity is similar between hESCs and diﬀerentiated
cells and cytoplasmic p can activate apoptosis in hESCs, we next examined two
potential mechanisms that might explain the p-dependent apoptosis observed
only in undiﬀerentiated cells. e ﬁrst is that cytoplasmic p is active exclu-
sively in undiﬀerentiated cells. e second is that cytoplasmic p is active in both
diﬀerentiated and undiﬀerentiated cells, but other intrinsic properties of hESCs
aﬀect their sensitivity to damage. Speciﬁcally, recent studies showed that mito-
chondrial priming determines the survival of various cancer cells (Ni Chonghaile
et al., , Vo et al., ). We therefore ﬁrst explored whether undiﬀerentiated
cells are intrinsically more “primed” for apoptosis than diﬀerentiated cells. Us-
ing BH proﬁling tomeasureMOMP induced by pro-apoptotic BH-only peptides
(Chonghaile et al., ), we found that undiﬀerentiated cells underwent MOMP
more readily than diﬀerentiated cells in response to each peptide in the panel, at
all concentrations (Figure .A). To better connect mitochondrial priming with
diﬀerentiation we measured the priming level during the course of RA diﬀerenti-
ation. Our results show a consistent trend: mitochondrial priming was highest in
undiﬀerentiated cells and decreased gradually with each additional day of diﬀer-
entiation (Figure .B). We further showed that two other hESC lines were more
primed than their diﬀerentiated progeny (Figure .A), suggesting that the cor-
relation between priming and pluripotency is not limited to one speciﬁc hESC line.
What might lead to high mitochondrial priming in hESCs? We ﬁrst tested
whether p itself contributes to high priming in undiﬀerentiated cells. Silencing

Figure 2.10: BH3 proﬁling reveals high priming of hESCs toward apoptosis.
(A). Heat map of mitochondrial depolarization (percentages indicated by colorbar)
caused by BH3-only peptides at the indicated concentrations (µ) in hESCs and dif-
ferentiated cells, for the three cell lines H1, CHB8, and HUES9. (B). Heat map of
mitochondrial depolarization caused by BH3-only peptides in hESCs treated with  µ
RA for 0, 1, 2, 3, and 4 days.
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of p did not reduce priming; in fact, we found a slight increase in priming com-
pared with hESCs expressing scramble shRNA (Figure .A). Hence, hESCs can
remain highly primed towards apoptosis independently of p. Next, we sought
to probe the status of the apoptotic machinery by measuring levels of pro- and
anti- apoptotic proteins in hESCs and their diﬀerentiated progeny (Figure .B).
While most proteins showed comparable levels between undiﬀerentiated and
diﬀerentiated cells, we observed two diﬀerences that are consistent with the cor-
relation between priming and pluripotency. Speciﬁcally, hESCs had lower levels
of the anti-apoptotic protein Bcl- and higher levels of the pro-apoptotic protein
PUMA (Figure .B). Counterintuitively, undiﬀerentiated cells showed higher
levels of the anti-apoptotic protein Mcl-. Taken together, these results suggest
that Mcl- is not a major determinant of priming in hESCs; instead, the basal
balance between other anti- and pro-apoptotic proteins, such as Bcl- and PUMA,
contributes to the diﬀerential priming of undiﬀerentiated and diﬀerentiated
cells.
We next asked whether perturbing the balance between pro-and anti-apoptotic
proteins can enable diﬀerentiated cells to activate apoptosis. We used ABT-, a
BH-mimetic drug that binds and inhibits anti-apoptotic proteins including Bcl-
(Tse et al., ), and wemeasured c-PARP after DNA damage. We found that dif-
ferentiated cells treated with ABT- successfully activated apoptosis after dam-
age (Figure .A).is result suggests that the intrinsic balance of pro-apoptotic
and anti-apoptotic proteins is closer to the apoptotic threshold in undiﬀerenti-
ated cells than it is in diﬀerentiated cells. Perturbation of this balance in diﬀeren-
tiated cells changes their priming and leads to apoptosis. Notably, accumulation
of c-PARP after damage in hESCs treated with ABT- did not exceed that in cells

Figure 2.11: Priming in hESCs is dependent on the balance between anti-
and pro-apoptotic proteins. (A). Heat map of mitochondrial depolarization caused
by BH3-only peptides at the indicated concentrations (µ) in scramble shRNA and
p53shRNA hESCs. (B). Immunoblots of pro- and anti-apoptotic proteins in hESCs
and diﬀerentiated cells. Colored in red are proteins that show diﬀerential levels be-
tween hESCs and diﬀerentiated cells.

not treated with ABT- (lanes  and  of Figure .A), suggesting that hESCs
are already highly primed.
e observation that diﬀerentiated cells can trigger apoptosis when treated
with ABT- suggests that p is fully functional in these cells. We have shown
that apoptosis in undiﬀerentiated cells results from p cytoplasmic activity. To
determine whether cytoplasmic p is active only in hESCs and not in diﬀerenti-
ated cells, we tested the localization of p in diﬀerentiated cells and the ability of
cytoplasmic p to activate apoptosis in diﬀerentiated cells treatedwith ABT-.
First, we found that a small fraction of p was also localized to the cytoplasm in
diﬀerentiated cells (Figure .B). Next, we diﬀerentiated hESCs silenced for p
and infected them with cytop and wtp. Diﬀerentiated cells expressing the
exogenous wtp showed behavior similar to that of their parental cells; they did
not die after damage unless treated with ABT- (Figure .C). Interestingly,
diﬀerentiated cells expressing cytop also induced apoptosis after DNA damage
under ABT- treatment, showing that cytoplasmic p is functional in diﬀeren-
tiated cells, but lowermitochondrial priming in these cells prevents the activation
of apoptosis in response to DNA damage.
In summary, we have shown that p exhibits similar apoptosis-inducing be-
havior in both undiﬀerentiated and diﬀerentiated cells. However, diﬀerentiated
cells are far from the apoptotic threshold, and p is unable to overcome this bar-
rier. Only when the balance of pro- to anti-apoptotic proteins is altered in diﬀer-
entiated cells can p push cells toward apoptosis. In contrast, p can success-
fully push hESCs past the apoptotic threshold due to their highly primed state
(Figure .).
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Figure 2.12: Increasing priming in diﬀerentiated cells leads to apoptosis after
damage. (A). Immunoblot of c-PARP, p53, and Oct4 in hESCs and diﬀerentiated
cells, untreated, treated with 100 ng/ml NCS for 3 hours, or treated with the indi-
cated concentration of ABT-263 for 4 hours (1 hour pre-treatment when combined
with NCS). (B). Immunoblot of p53 and c-PARP in the nuclear and cytoplasmic frac-
tions of hESCs and diﬀerentiated cells. Cells were undamaged or damaged with NCS
for 3 hours. Histone H4 and the transcription factor Rb serve as nuclear markers, and
tubulin as a cytoplasmic marker. N = nuclear, C = cytoplasmic. (C). Immunoblot of
c-PARP, p53, and Oct4 in cells diﬀerentiated from p53shRNA hESCs (p53sh), and
where indicated, infected with wtp53 and cytop53 constructs. Prior to infection, cells
were diﬀerentiated with  µ RA then passaged twice, maintaining RA in the media.
All cells were treated with NCS for 3 hours, and where indicated, pre-treated with
 µ ABT-263 for 1 hour before NCS addition.
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Figure 2.13: The proximity of hESCs, unlike diﬀerentiated cells, to the apop-
totic threshold makes them sensitive to increased p53 after damage. Mito-
chondrial priming is depicted as proximity to the cliﬀ’s edge (the apoptotic threshold).
A cell, shown as a green ball, is at distance x from the edge if it is an hESC, and
at distance x from the edge if it is diﬀerentiated, where x > x. Prior to damage,
basal low levels of p53, represented as a red cartoon, are insuﬃcient to push either an
hESC or a diﬀerentiated cell over the cliﬀ. Damage causes p53 to accumulate in both
hESCs and diﬀerentiated cells to similar levels, with similar functions. The distance
that p53 pushes the cell towards the cliﬀ is represented by the displacement y for the
hESC and y for the diﬀerentiated cell, where y = y. For an hESC, y > x, suﬃc-
ing to push the cell over the cliﬀ, crossing the apoptotic threshold and leading to cell
death. In contrast, a diﬀerentiated cell is too far away from the edge (y < x), so
p53 function is insuﬃcient to push the cell beyond the apoptotic threshold, allowing
the cell to survive after damage.

. D
A cell’s decision among diﬀerent cell fates is especially critical in response to chal-
lenging inputs such as DNA damage. Diﬀerent cell types meet this challenge in
a variety of ways. In cell types where maintenance of genomic integrity is cru-
cial, such as hESCs, one might expect that signaling pathways are poised to cope
with DNA damage aggressively by selecting terminal cell fates such as apoptosis.
Here we show that hESCs usemultiple pathways to ensure apoptosis is induced af-
ter damage, including activation of p transcription and cytoplasmic functions
and high mitochondrial priming. We have shown that in hESCs p’s transcrip-
tional activity is not required to induce apoptosis; rather, cytoplasmic p is suﬃ-
cient for induction of apoptosis without transcription of downstream p target
genes. Yet pro-apoptotic p target genes such as PUMA, NOXA, and APAF are
up-regulated after damage in a p-dependent manner, suggesting that hESCs
may use the p transcriptional pathway as a second line of defense to ensure cell
death in case cytoplasmic p fails to do so.
We have shown here that cytoplasmic p contributes to induction of apopto-
sis in hESCs. However, the mechanisms by which cytoplasmic p exerts its func-
tion remain open. A recent study showed that hESCs maintain active Bax that
rapidly localizes from the Golgi to the mitochondria after damage, and that this
translocation is p-dependent (Dumitru et al., ). e role of p in generat-
ing the translocation of active Bax, however, remains unclear. Interestingly, this
mechanism was employed to various extents by diﬀerent hESC lines; the cell line
primarily used in our study, H, did not show active Bax under basal conditions
(Dumitru et al., ). Yet we show here that H cells also undergo rapid apopto-
sis after DNA damage, suggesting cytoplasmic p can trigger the same end result

via other mechanisms.
While we have shown that the levels of the anti-apoptotic protein Bcl-
and the pro-apoptotic protein PUMA are consistent with the high priming in
hESCs in comparison with diﬀerentiated cells, the complete network that de-
termines mitochondrial priming is likely to involve additional players. Even for
apoptosis-regulating proteins that show similar levels in undiﬀerentiated and
diﬀerentiated cells (Figure C), speciﬁc modiﬁcations, localization, and protein
interactions might aﬀect their function and therefore generate diﬀerential prim-
ing. Furthermore, the relationship between priming and pluripotency might
depend on other networks. For example, pluripotency is known to be linked to
rapid cell cycle progression (Filipczyk et al., ), whichmay directly or indirectly
aﬀect the apoptotic machinery. Complete understanding of the mechanisms con-
trolling priming will require global analysis of protein function and interaction in
multiple pathways.
. M  
Cell culture: Experiments were performed on H hESCs except where otherwise
mentioned. H (also called WA) was obtained from WiCell. CHB, HUES,
and HUES p-/- were kindly provided by George Daley, Doug Melton, and Yang
Xu (Song et al., ) respectively. Cell culture was performed as previously de-
scribed (Lerou et al., ). Brieﬂy, hESCs were cultured feeder-free on plates
treatedwith hESC-qualiﬁedMatrigel (BDBiosciences) inmTeSR-medium (Stem-
cell Technologies). e medium was changed daily, and cells were passaged every
- days with  mg/ml Dispase (Stemcell Technologies). Diﬀerentiation of hESCs
was induced by adding  µM RA (Sigma), with a fresh medium change daily.

Antibodies and reagents: Antibodies were used against p (DO, Santa Cruz),
actin (Sigma), Oct (Abcam), cleaved PARP- (Epitomics), PUMA (Cell Signaling),
Histone H (Santa Cruz), tubulin (Developmental Studies Hybridoma Bank),
￿-HAX (JBW,Millipore), Bad (Santa Cruz), Bak (Millipore), Bax (Santa Cruz),
Bid (Atlas), Bim (Cell Signaling), Mcl- (Cell Signaling), Bcl- (Santa Cruz), and
Bcl-xL (Cell Signaling). Neocarzinostatin was obtained from Sigma and Nutlin-a
from Cayman Chemical.
Flow cytometry: Cell-cycle distributionswere analyzed using propidium iodide.
Annexin V measurements were performed using the Annexin V PE Apoptosis De-
tection Kit (eBioscience). Analysis was done in FlowJo and Matlab.
qRT-PCR: Total RNA was isolated using the RNeasy Mini Kit (Qiagen). cDNA
was generated with the High-Capacity cDNA Reverse Transcription Kit (Applied
Biosystems). For qPCR, reaction mixes were set up in triplicate using Power SYBR
Green Master Mix (Applied Biosystems) and run using the CFX Real-Time Sys-
tem (Bio-Rad). mRNA levels were normalized to GAPDH expression, then relative
expression calculated as fold-change from the untreated control.
Immunoblotting: Cells were harvested and protein extracts obtained by lysis in
the presence of protease and phosphatase inhibitors. Total protein amount was
quantiﬁed using the BCA assay (Pierce). Equal protein amounts were separated by
electrophoresis on – Bis-Tris gradient gels (Invitrogen) and transferred to
PVDF membranes by electroblotting. Membranes were blocked with  non-fat
dried milk, incubated with primary antibody, washed, and incubated with sec-
ondary antibody coupled to horseradish peroxidase. Protein levels were detected
using chemiluminescence (ECL , Pierce) after additional washing steps.
Immunoﬂuorescence: hESC colonies were grown onMatrigel-coated glass cov-

erslips, ﬁxed in  paraformaldehyde, permeabilized with . Triton X-, and
blocked in  BSA in PBS. Cells were incubated with primary antibody overnight
at o C, washed, and incubated with Alexa Fluor-conjugated secondary antibody
(Invitrogen) and counterstained with DAPI (Life Technologies).
siRNA knockdown: hESCs were dissociated into single cells in the presence of
 µ Y (StemGent) with Accutase (Stemcell Technologies) and plated at
a density of    cells per well of a -well plate. e following day, cells were
transfectedwith  pmol siRNA (Dharmacon) per well usingDharmafect trans-
fection reagent. Media was changed  hours post-transfection, and experiments
were performed - hours post-transfection.
Cell line construction: e pshRNA construct with a blasticidin resistance
cassette was kindly provided by the Agami lab (Brummelkamp et al., ). e
cytop and wtp constructs are resistant to this pshRNA due to silent point
mutations described further below. e lentiviral vectors for cytop and wtp
were created using standard molecular biology techniques to include an upstream
ubiquitin promoter, p, and an mVenus tag. Point mutations for the KA and
RA amino acid substitutions in the NLS region of p for the cytop con-
struct were introduced using site-directed mutagenesis (Quikchange kit, Agilent).
T cells were transfected with the Agami lab pshRNA construct and vi-
ral packaging vectors using the Mirus- transfection reagent, and viral super-
natant was collected and concentrated. For viral infection, hESCswere dissociated
and plated as described above for siRNA transfection. e following day, cells were
infected with virus in media containing HEPES and protamine sulfate. Cells were
allowed to recover in nonselective media for one day. Cells were thereafter main-
tained in  µg/ml blasticidin (InvivoGen), and a clonal line was selected from a

single colony.
e cytopandwtp constructs are resistant to the aforementionedpshRNA,
as their cDNA sequences contain the following  silent point mutations preserv-
ing the amino acid sequence: CT, TA, CG, AT, GC, TA and
TC. ese point mutations were introduced using site-directed mutagenesis
(Quikchange kit, Agilent) with the following primers:
’-cctcaccatcatcacactggaggatagctctggaaacctactgggacggaacagctttgag-’ and
’-ctcaaagctgttccgtcccagtaggtttccagagctatcctccagtgtgatgatggtgagg-’.
For the cytop construct, point mutations for the KA and RA amino acid
substitutions in the NLS region of p were introduced (Quikchange) using the
following primers:
’-ctgcccccagggagcactgcggcagcactgcccaac-’ and
’-gttgggcagtgctgccgcagtgctccctgggggcag-’.
e sameviral production and infectionprocedureswere used as for thepshRNA
construct.
BH proﬁling: hESCs were dissociated with Accutase, counted, and suspended
in DTEB buﬀer ( mM trehalose,  mMHEPES,  mM KCl,  µM EDTA, 
µM EGTA,  mM potassium succinate, ﬁnal pH .) at :   cells/mL. e
cells were then added to an equal volume of X staining mastermix ( µM JC-,
 µg/mL oligomycin,  mM -mercaptoethanol,  µg/mL digitonin in DTEB
buﬀer) and allowed to stain for minutes at RT.  µL of stained cells were added
to wells containing  µL of peptides at X ﬁnal concentration in DTEB to yield
the ﬁnal proﬁling plate with  cells/well. Fluorescence at  nm was mon-
itored using  nm excitation on a Tecan Saﬁre  at a controlled temperature
of C with automated readings every ﬁve minutes. e area under each pep-

tide response curve was calculated using Graphpad Prism, and these areas were
normalized to the internal FCCP and DMSO controls as Depolarization () =  –
([sample-FCCP]/[DMSO-FCCP]).
. M 
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
A model is a lie that helps you see the truth.
Howard Skipper
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p regulation of cell fate in response to
cisplatin
I  , one important goal is to eradicate cancer cells while preserv-
ing healthy cells. While our understanding of the genes and pathways that are
dysregulated in cancer cells is increasing, we for the most part still have not de-
veloped methods to reliably target only those cells with the abnormalities. One
challenge is that cancer cells themselves are a heterogeneous population that do

not all respond in the same way to identical treatment. When treated with a drug,
some fraction of cancer cellsmight diewhile others recover and survive. is resis-
tant population can eventually lead to tumor regrowth and acquire newmutations
conferring further resistance. us, understanding what determines diﬀerential
responses to chemotherapy drugs and manipulating these responses to improve
therapeutic eﬃcacy will be crucial.
. C   
One of the most eﬀective broad-spectrum cancer drugs, cisplatin was acciden-
tally discovered to inhibit Escherichia coli bacterial growth and only later was found
to have anti-tumor activity (Shen et al., ). e mechanism of action of this
small-molecule platinum compound is the formation of crosslinks in DNA, both
inter-strand and intra-strand, as well as protein-DNA crosslinks. DNA crosslinks
pose threats to normal cellular function, as they can interfere with transcription
and cause stalled replication forks (Ide et al., , Vare et al., ). e DNA
adducts are detected by various DNA damage-sensing and repair pathways, as well
as several important signaling pathways such as theAkt, p, andMAPKpathways
(Wang and Lippard, ).
Cisplatin is commonly used as a part of the treatment regimen for many solid
tumor types, including head and neck, testicular, ovarian, cervical, lung, and col-
orectal cancers (Shen et al., ). Despite its widespread use, cisplatin therapy
has several limitations, including toxicity and both inherent and acquired resis-
tance. Even when a patient has a good initial response to cisplatin, often the de-
velopment of cisplatin resistance results in relapse and diminished eﬀectiveness
(Siddik, ). Moreover, given the heterogeneity of cancer cells within a tumor,

fractional killing can result in some surviving cells that can seed tumor repopula-
tion. Hence, the question of how drug treatment can lead to diﬀerential cell fate
outcomes is of critical importance.
As colon cancer is one of the types of cancer treated by platinum-based com-
pounds in the clinic, we undertook our study in HCT colon cancer cells. To de-
termine how cisplatin aﬀects HCT cell viability, we generated a dose response
curve. e response of HCT to diﬀerent doses of cisplatin was determined
using the CellTiter-Glo assay (Promega), which measures ATP content as a proxy
for cell viability. e dose response curve showed that ATP content decreasedwith
increasing levels of cisplatin, and reached its half-maximal value at a cisplatin con-
centration of : µ (Figure .A). We further characterized how a population of
cells responds to this IC concentration of cisplatin by imaging and tracking cells
by microscopy for  hours. At : µ cisplatin, approximately half of the cells
die and half survive. Of the cells that die, the median time of death was  hours.
e Jarque-Bera test conﬁrmed that death times were normally distributed, and
hence it can be inferred that  of cells that undergo apoptosis will die within 
hours (Figure .B).
Cisplatin-treated cells show a marked decrease in cell divisions. Compared to
cells not treated with cisplatin, most of which completed  cell divisions in 
hours, cells treated with cisplatin rarely divided more than once (Figure .C). In
a replating assay (Purvis et al., ), in which cells were replated after the 
hour period and observed each day for the following  days, untreated cells con-
tinued to divide, while cells that survived the cisplatin treatment did not divide
(Figure .D). ey also spread out and became very large, with a high cytoplas-
mic to nuclear ratio. ese features are characteristic of senescent cells. From

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Figure 3.1: Cells treated with cisplatin undergo apoptosis or senescence. (A)
ATP content, representing cell viability, as assayed by CellTiter-Glo on HCT116 cells
treated with varying concentrations of cisplatin for 72 hours. (B) Probability density
function for the distribution of death times of apoptotic cells after : µ cisplatin
treatment. (C) Proportion of the cell population undergoing 0, 1, 2, or 3 divisions in
72 hours, untreated or after cisplatin. (D) Proportion of the cell population under-
going 0, 1, 2, 3, or 4 divisions in the 5 days after replating 72 hours after cisplatin
treatment.

these data we infer that the half of the population that do not die instead enter
senescence.
. D    
Variation in tumor response to cisplatin is inﬂuenced by the genetic background
of the tumor cells. As the tumor suppressor p is frequently mutated in cancer,
many studies have evaluated the impact of its presence or absence on cisplatin
sensitivity. While some studies suggest that p status has little eﬀect on cellular
response to cisplatin (Oliver et al., ), it has been found that wild-type p
function in a National Cancer Institute (NCI) panel of  human cancer cell lines
correlates positively with sensitivity to cisplatin (Vekris et al., ). Moreover, in
ovarian cancer patients, p alterations correlate signiﬁcantly with resistance to
platinum-based chemotherapy, early relapse, and shortened overall survival (Re-
les et al., ). at p mutations may confer higher resistance to cancer cells
implies that loss of p inhibits the transmission of the DNA damage signal to
the apoptotic machinery (Siddik, ). Hence, p may play an active role in
promoting apoptosis or other terminal cell fates in cells damaged by cisplatin. We
therefore investigated post-cisplatin p behavior and function in the HCT
cell line, which is wild type for p.
To survey the p response to cisplatin in single living cells, we measured p
using a ﬂuorescent reporter construct. In our HCT background, the ﬂuores-
cent protein mVenus was inserted at the ’ end of exon  of one allele of p.
e second p allele was unaltered. is HCT knock-in reporter cell line was
treated with cisplatin and the level of p represented by the intensity of mVenus
ﬂuorescence was monitored by long-term time-lapse ﬂuorescence microscopy ev-

ery  minutes for  hours. We veriﬁed that the HCT p-mVenus knock-in
(HCTpVKI) cell line showed similar dynamics of cell death after cisplatin
treatment as the wild-type HCT line (Figure .A). Moreover, we veriﬁed
that post-cisplatin induction of apoptosis is to an extent dependent on p, as
HCT p-/- cells were more resistant to cisplatin treatment. To test that the
Venus reporter for p was faithful to the endogenous p, we measured protein
levels in the HCTpVKI cell line treated with cisplatin and conﬁrmed that
p-mVenus dynamics resembled those of endogenous p (Figure .B). p
levels increase gradually after cells are treated with cisplatin, indicating that the
p pathway is responsive to cisplatin-caused damage. On the single cell level, we
observed that the dynamics of p accumulation were highly variable across cells.
is spread suggests that p dynamics in individual cells could contribute to the
decision between diﬀerent downstream outcomes, as approximately half of the
cells undergo apoptosis while the other half undergo senescence.
Severalmodels have been suggested for how activation of pmight induce dif-
ferential downstream outcomes. e aﬃnity model proposes that pmight have
diﬀerent aﬃnities for the promoters of downstream target genes eﬀecting diﬀer-
ent outcomes, such as cell cycle arrest and apoptosis (Inga et al., ). us, if
cell cycle arrest genes have promoters with high p aﬃnity, they will be upregu-
lated even with low p expression, whereas apoptotic genes with promoters with
low p aﬃnity will not be expressed until p accumulates to a high level. If
this model were true, one would expect that low p induction would lead to ex-
pression of only cell cycle arrest target genes and not apoptotic target genes. In
contrast to the aﬃnity model, the threshold model does not rely on diﬀerences
in p binding aﬃnity but rather hypothesizes that the diﬀerent types of p
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Figure 3.2: HCT116 expressing p53-Venus reliably represent wild-type
HCT116. (A) Percentage of cells remaining alive as measured by microscopy after
cisplatin treatment in three cell lines, HCT116 p53-/-, HCT116 p53+/+ (wild-type),
and HCT116 with p53-mVenus knock-in (p53VKI). (B) Immunoblot of HCT116VKI
protein levels at the indicated times after treatment with : µ cisplatin. Actin
serves as a loading control.
target genes are concurrently expressed to the degree to which p is expressed
(Kracikova et al., ). Low levels of p and hence low levels of its arrest and
apoptotic targets will not cross the apoptotic threshold, but high levels of p for
a long duration will result in increased expression of all target genes, including
apoptotic ones, and eventually will cross the apoptotic threshold.
Analysis of the traces of p in cells that died after cisplatin treatment and
cells that survived for at least  hours showed that the maximal level reached
by p was similar in both groups (Figure .A). Binning cells by their maximal
p levels revealed no trend in the proportion of cells undergoing apoptosis (Fig-
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Figure 3.3: Maximal levels of p53 do not distinguish apoptotic from surviving
cells. (A) The maximal p53 value of each cell is plotted as an open circle, with the
red line denoting the mean, the pink the standard error of the mean, and the lavender
the standard deviation. (B) Cells were binned by maximal p53 levels and the percent-
age of apoptotic cells was plotted for each bin.
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Figure 3.4: Rate of p53 accumulation diﬀers in apoptotic and surviving cells.
(A) The rate of p53 increase (slope of p53 from 50% to 90% of max) of each cell is
plotted as an open circle, with the red line denoting the mean, the pink the standard
error of the mean, and the lavender the standard deviation. (B) Cells were binned by
p53 accumulation rates and the percentage of apoptotic cells was plotted for each
bin. (C) The p53 levels over time (x-axis) for individual cells (rows) plotted as a heat
map, with the colorbar as indicated (a.u.) White arrow delineates the time point at
which half of the apoptotic cells (left) have induced p53.

ure .B), suggesting that cells with higher p are not more likely to undergo
apoptosis. is implies that the decision between death and survival cannot be
made based only on p levels, as is proposed in both the aﬃnity and the thresh-
old models. Instead we observed that the rate of p accumulation, measured
by the slope from the half-maximal value of p to the point when p reaches
 of its maximal value, was faster in the cells that underwent apoptosis (Fig-
ure .A). is diﬀerence in p induction rate between dying and surviving cells
was signiﬁcant (p < :), and binning cells by p induction rate showed an
increasing trend of greater proportion of apoptosis in cells that induce p faster
(Figure .B). When the individual traces of p expression of apoptotic and sur-
viving cells were plotted in a heat map and sorted by time of p induction, we
observed that the apoptotic cells tended to accumulate p earlier (Figure .C).
Shortly before  hours, when p levels had risen in half of the apoptotic cells,
p had been induced in only a small fraction of the surviving cells.
Altering the dose of cisplatin changed the rate of p accumulation and the
choice of cell fate. At half the concentration of cisplatin, : µ, we observed
a longer lag before p accumulated, and only . of cells died (Figure .A).
Consistently, at double the concentration of cisplatin,  µ, the timing of p
increase occurred earlier, and almost all cells (.) died. For each concentra-
tion, the maximal p level reached was only slightly diﬀerent between apoptotic
and surviving cells (Figure .B), with the exception at the highest cisplatin dose,
where the sample size of surviving cells was small. While the maximal p level
was not predictive of cell fate, p was induced earlier with increasing cisplatin
concentration, correlating with higher proportion of apoptotic cells (Figure .C).

Figure 3.5 (following page): Increasing concentrations of cisplatin promotes
faster p53 increase and increased death. (A) The p53 levels over time (x-axis)
for individual cells (rows) plotted as heat maps, with the colorbar as indicated (a.u.)
Top, : µ cisplatin. Middle, : µ cisplatin. Bottom,  µ cisplatin. (B) Max-
imal p53 levels reached for apoptotic and surviving cells at the indicated dose of cis-
platin. (C) Time at which cells reached their half-maximal p53 value, for each dose
of cisplatin. (D) Time at which cells reached their half-maximal p53 value, for each
dose of cisplatin, separated between apoptotic and surviving cells. Error bars repre-
sent standard deviation.
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Figure 3.5: (continued)
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Figure 3.6: Dynamic threshold model of p53-induced apoptosis. Single-cell
traces of p53 levels after : µ cisplatin treatment were divided into time windows,
then binned by the maximal p53 value reached in each time window. Each bin was
colored by the proportion of cells from that bin that eventually underwent apoptosis.
Indeed, consistent with Figure ., at each cisplatin concentration the apoptotic
cells activated p earlier than the surviving cells (Figure .D). ese data sug-
gest that higher doses of damage causemore cells to induce p earlier, and earlier
induction of p leads to a higher probability of cell death.
. A   - 
We analyzed the probability that a cell eventually will die given the maximal level
of p reached within a certain time window. is probability was computed by
ﬁrst dividing up the initial  hours after : µ cisplatin treatment into -hour
time windows (the time elapsed from  hours onwards was grouped into one
window). For each segment of time, the p traces were binned by the maxi-
mal p value reached within that timeframe. e bins were then colored in a
heatmap representing the proportion of cells from that bin that eventually un-

derwent apoptosis. e resulting matrix shows that as time progresses, the level
of p at which cells become likely to undergo apoptosis progressively increases
(Figure .). Stated another way, if a cell’s p level has not crossed the apoptotic
threshold in one window, then in the following window it will have to surpass
an even higher threshold for the cell to die. is suggests that there may be a
threshold for triggering apoptosis, but that the threshold changes and becomes
increasingly high over time. We named this the dynamic threshold model.
e dynamic threshold model suggests that forcing a faster increase of p at
early times after cisplatin treatment should increase the proportion of dying cells
relative to surviving cells. In contrast, further increase in p at later time points
should lead to a smaller increase in apoptotic cells. To test this hypothesis, at dif-
ferent times after cisplatin treatment we also added Nutlin-a (nutlin), the afore-
mentioned small molecule that disruptsMdm binding to p and thus facilitates
p accumulation (Vassilev et al., ). Adding nutlin and causing p levels to
increase early, at  hours after cisplatin, dramatically increases the proportion of
cells undergoing apoptosis rather than surviving (Figure .). In contrast, adding
nutlin at  hours raises p to similarly high levels, yet a much smaller increase
in the number of dying cells results. ese ﬁndings indicate that the timing of p
elevation is crucial for the decision to enter apoptosis.
As p dynamics play a role in regulating cell fate via diﬀerential activation of
downstream target genes (Purvis et al., ), we hypothesized that faster p ac-
cumulationmight lead to increase in expression of pro-apoptotic p target genes,
or that slower p might allow cells to prevent apoptosis due to expression of
p target genes that trigger cell cycle arrest, which could antagonize apoptosis.
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Figure 3.7: Addition of nutlin at diﬀerent times after cisplatin inﬂuences cell
fate. (A) The p53 levels over time (x-axis) for individual cells (rows) plotted as heat
maps, with the colorbar as indicated (a.u.) Top, cisplatin only. Middle, cisplatin with
 µ nutlin addition at 3 hours (indicated by white dashed line). Bottom, cisplatin
with nutlin addition at 30 hours (white dashed line). (B). The percentage of apop-
totic cells observed in the indicated conditions (cisplatin only, nutlin only, cisplatin
with nutlin addition at 3 hours, and cisplatin with nutlin addition at 30 hours).

BA
Apoptotic cells Surviving cells
M
ax
 p
21
 le
ve
ls
 (a
.u
.)
1000
2000
3000
4000
Time (h)
p2
1 
le
ve
ls
 (a
.u
.)
0 10 20 30 40 50 60 70
0
500
1000
1500
2000
2500
3000
3500
Figure 3.8: p21 levels increase after cisplatin treatment. (A) Median p21p-CFP
trace (solid) of HCT116p53VKI-p21p-CFP cells after cisplatin treatment. Dashed
lines show the 25th and 75th percentiles.(B) The maximal p21 value of each cell is
plotted as an open circle, with the red line denoting the mean, the pink the standard
error of the mean, and the lavender the standard deviation.
e p target p is known to play a role in arrest, and cells with disrupted p
genes have been shown to be more sensitive to cisplatin (Fan et al., ). e in-
creased apoptosis due to loss of p suggests that p has a protective eﬀect and
promotes survival. To measure the downstream eﬀects of p induction, we em-
ployed a p promoter construct that contains the p-responsive elements from
the p promoter driving the expression of the ﬂuorescent protein CFP. Incorpo-
rating this pp-CFP construct into HCT pVKI cells via lentiviral infection
allowed us to monitor the p-dependent mRNA expression of p. We observed
that p expression increased robustly in cisplatin-treated cells (Figure .A). Sur-
viving cells appeared to have higher maximal p levels than apoptotic cells (Fig-
ure .B).
ese data led us to consider a quantitative model in which the outcome of p

signaling, either apoptosis or survival, depends on the rate of p accumulation.
As p is induced, it will upregulate transcription of some apoptotic targets, for
instance PUMA, that promote apoptosis. At the same time but with some delay,
pwill upregulate p, whichwill promote arrest and senescencewhile inhibiting
apoptosis, rescuing the cell from death (Figure .A). Such a delay in p-induced
p expression can be generated with a coherent feed forward loop through a pu-
tative molecule X (Mangan and Alon, ). Expanding a previously published
model (Batchelor et al., ), we modeled the system with delayed diﬀerential
equations as the following:
dp
dt
= p (.)
dPUMA
dt
= PUMAp(t  PUMA)  PUMAPUMA (.)
dX
dt
= Xp(t  X)  XX (.)
dp
dt
= pp(t  p)X(t  p)  pp (.)
dApop
dt
= ApopPUMA  Apopp (.)
where p, PUMA, X, p, and Apop are the species, each with production terms
with constants andﬁrst order degradation termswith constants. e equation
for p does not have degradation because it acts more as a driving function for
the system and is independent of the other components. Apop is a variable that
loosely represents the apoptotic signal in the cell, with the assumption that when
Apop crosses a threshold the cell is committed to death. e equation for Apop also
does not have ﬁrst order degradation, as instead its degradation depends on p.
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Figure 3.9: A model of the p53 network in response to cisplatin. (A) A dia-
gram showing p53 induction of PUMA, which activates apoptosis. Also, p53 induces
p21, which represses apoptosis. To create a delay in p53-induced p21 expression, a
feed-forward loop connects p53 to p21 via a putative molecule X. (B) With increasing
rates of p53 accumulation, the variable representing apoptosis reaches higher levels,
triggering cell death when it crosses a threshold (dashed line).

With the very simplistic condition that p is linearly increasing (Equation.),
parameters can be found such that the variable representing apoptosis will cross a
threshold with a fast p increase but not with a slow p increase (Figure .B).
is model predicts that p expression follows p expression but varies nonlin-
early, so that after a delay, p is expected to increase much faster at higher rates
of p accumulation (Figure .B). However, for the rightmost two cells with high
p rate in (Figure .B), the apoptosis variable crosses the threshold at a point
when p level is still low. e leftmost two cells with low p rate survive and in
these cells p accumulates to high levels. is explains the diﬀerence in themax-
imal levels of p observed between apoptotic and surviving cells. Larger datasets
and further analysis of individual cell traces of p expression will be needed to
substantiate the dynamics of p predicted by the model.
. D
e quantitative model can be expanded and improved in a number of ways. e
linear increase in p is an over-simpliﬁcation, and should be modiﬁed so that
p levels increase after some delay. Furthermore, p levels should eventually
plateau, since we observe that apoptotic cells that accumulate p quickly have
similar maximal p levels as the surviving cells that accumulate p slowly. at
the cells with fast-increasing p die, however, should be considered; because once
the cell dies, the p level at later time points as predicted by the model is irrele-
vant, it may not be essential to explicitly write a limit for p into the equations.
e model should also be adjusted to more accurately reﬂect the dynamic thresh-
old for p activation of apoptosis; for instance, whether or not the molecule rep-
resenting apoptosis crosses its threshold should correspond to whether p has

crossed its time-dependent increasing threshold. Further possible geometries of
the p network should be explored in greater depth. Because cell death and sur-
vival are also only probabilistically predicted by p dynamics (Figure .), one
might also consider stochastic models for this system.
What regulates the choice between death and survival downstream of p is
still not completely understood. Multiple pro-apoptotic or pro-arrest p target
genes may be important for this cell fate decision. e dynamics of p, for in-
stance, are potentially one mechanism set in place to rescue the cell from apop-
tosis if the apoptotic signal is not strong enough. Such a hypothesis would sug-
gest that one or more pro-apoptotic p target genes follow p dynamics quite
faithfully, such that when p increases early and rapidly, target gene expression
also increases and triggers apoptosis before p has had a chance to accumulate.
When p accumulation is slower, the pro-apoptotic target genes also follow, but
p continues to build up and thus prevents apoptosis. One might also imagine
that the increase in p after cisplatin provides a natural source for the proposed
dynamic threshold model; as time goes on, any p-dependent apoptotic signal
must overcome higher and higher levels of p.
We currently are planning further experiments to verify that p is a factor
that inhibits apoptosis and promotes survival. We are generating cells lacking
p due to stable expression of p shRNA and will evaluate cisplatin-induced
cell fate in these cells, expecting that p knockdown should increase the propor-
tion of apoptotic cells. Based upon the model, a search for the putative molecule
X could start with p target genes that may also inﬂuence expression of p,
though perhaps not directly. e p target HIC is a potential candidate that
may positively regulate p transcriptional activity (Chen et al., ). Further

testing will be required for any candidate genes. We are additionally building a
ﬂuorescent reporter similar to the p reporter to measure expression from the
promoter of the p pro-apoptotic gene PUMA. PUMA is a candidate for a p
target involved in promoting apoptosis after cisplatin treatment, since like p its
gene expression increases after cisplatin treatment as measured by qPCR. PUMA
dynamics will potentially shed light on how the behavior of p after cisplatin
regulates pro-apoptotic target genes.
Greater insight into how p dynamics inﬂuence cell fate decisions in cells
treated with cisplatin will prompt the development of methods to manipulate
those dynamics. e ability to modulate the dynamics of such network regulators
and predict the cellular outcomes has direct clinical relevance. Moreover, given
the wide use of chemotherapy to treat cancer, it is important to understand how
the function of drugs like cisplatin may vary in diﬀerent conditions and cancer
cell types. Only with such understanding will we be able to predict how eﬀective
various therapies will be and perhaps how best to use them in combination.
. M  
Cell culture: All HCT cell lineswere grown inMcCoy’smediawith  fetal calf
serum,  U/ml penicillin,  µg/ml streptomycin, and  ng/ml fungizone.
HCTp-/- cells were kindly provided by Bert Vogelstein. HCTpVKI
cellswere generated byAlexander Loewer via homologous recombination. Lentivi-
ral infection and clonal selection were used to generate HCTpVKI cells with
pp-CFP with the protocol described in Chapter .
Antibodies and reagents: Antibodieswere used against p (DO, SantaCruz) and
actin (Sigma). Cisplatin (Sigma) was stored as a solid, dissolved in DMSO at a high

concentration then further diluted in water and rapidly added to cells. Nutlin-a
was obtained from Cayman Chemical. e CellTiter-Glo assay was performed ac-
cording to manufacturer’s instructions (Promega).
Immunoblotting: Western blots were performed as described in Chapter .
Microscopy: Two days prior to microscopy, cells were grown in RPMI media lack-
ing riboﬂavin and phenol red to reduce medium autoﬂuoresence in poly-D-lysine-
coated glass-bottom plates (MatTek). Cells were imaged on a Nikon Eclipse
TE-E inverted ﬂuorescence microscope in which the stage was surrounded
by a custom enclosure to maintain constant temperature, CO concentration, and
humidity. Images were acquired with MetaMorph software (Molecular Devices).
Data were analyzed in MATLAB (Mathworks).
Computational modeling: Numerical integration was performed in MATLAB
(Mathworks). e source code is available upon request. e parameters shown
in Figure .B are presented in the following table.

Parameter Description Value
p p production rate .-
PUMA PUMA production rate .
PUMA Time delay in PUMA production .
PUMA PUMA degradation rate .
X X production rate .
X Time delay in X production .
X X degradation rate .
p p production rate .
p Time delay in p production 
p p degradation rate .
Apop Apop production rate 
Apop Apop degradation rate .
. M 
Author contributions: Andrew L. Paek conducted the experiments. Alexi Kedves
and Bill Forrester provided the data for (Figure .A). Andrew L. Paek and Julia
C. Liu performed the experimental analysis. Julia C. Liu performed the computa-
tional modeling and wrote this chapter.

ere is still the conspicuous asymmetry betweenmolecular bi-
ology and, say, the therapy of lung cancer.
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Conclusion
T        appropriately to diverse stim-
uli has broad implications in health and in disease. e signaling networks that
regulate cell fate decisions have interactions with other networks, including those
maintaining cell state and identity. ese interactions can give rise to heteroge-
neous outcomes between diﬀerent cell types as well as within a cell population.
Understanding how cells and tissues are poised to respond to stimuli will help us
to interpret and rectify alterations of these signaling networks in diseases such as

cancer.
In particular, cancer is often characterized by faulty cellular signal processing.
Among the hallmarks of cancer are continual retention of proliferative signaling
and the evasion of growth suppressive and cell death signals (Hanahan andWein-
berg, ). However, the nature of regulatory network dysregulation is not uni-
form across cancer tissues and cell types. In part this can be attributed to the
abundance of diﬀerent mutations that give rise to cancerous cells. Nonetheless,
even in the same cell line, variance in the dynamics of regulatory networks can lead
to diﬀerent downstream outcomes. As we discussed in Chapter , diﬀerences in
p dynamics across single cells correlate with alternative cell fates, apoptosis and
senescence.
e tissue of origin also plays a role in heterogeneity, as cells from diﬀerent
tissues often have very diﬀerent responses to stimuli. is variation becomes
clinically relevant as the DNA damage responses in diﬀerent tissues can vary and
thus confer diﬀerential sensitivity to radiation or chemotherapy (Gudkov and Ko-
marova, ). e underlying mechanisms conferring sensitivity or resistance
and how they vary with cell type are still open questions. Human embryonic stem
cells (hESCs) have a uniquely sensitiveDNAdamage response, whichwe character-
ized in Chapter . While apoptotic death in hESCs after damage is dependent on
p, we showed that it is hESCs’ proximity to the apoptotic threshold that makes
them vulnerable to p signaling (Liu et al., ). BH proﬁling of hESCs in the
process of diﬀerentiation reveals that as the cells diﬀerentiate, their priming grad-
ually decreases, suggesting that high mitochondrial priming in hESCs is closely
linked to pluripotency.

. C      ESC
How the highly primed state is created and maintained in hESCs is still an
open question. One potential mechanism is by controlling the balance between
pro- and anti-apoptotic proteins. Compared with diﬀerentiated cells, hESCs
have lower levels of the anti-apoptotic protein Bcl- and higher levels of the
pro-apoptotic protein Puma, consistent with the higher priming of hESCs. Yet
other apoptosis-regulating proteins, including Bid, Bim and Bcl-xL, showed simi-
lar levels in undiﬀerentiated and diﬀerentiated cells (Liu et al., ). It is unclear
whether speciﬁc modiﬁcations, localization, or protein interactions might aﬀect
how these proteins contribute to priming. As mentioned, some hESC lines main-
tain basally activated Bax, which provides a quick and direct route to apoptosis.
is close proximity to the apoptotic threshold is found only in undiﬀerentiated
cells, as just two days of diﬀerentiation of these hESCs into embryoid bodies were
suﬃcient for activated Bax to disappear, and for the cells to no longer undergo
apoptosis after damage (Dumitru et al., ). us, pluripotency seems to regu-
late the state of the cell to keep it highly primed and sensitive to damage, but our
understanding of the nature of this regulation is still limited.
e relationships between the molecular players in the pluripotency and the
priming networks could be complex and depend on other networks (Figure .).
e cell cycle network, for instance, appears to be uniquelymodiﬁed in hESCs. It is
well known that hESCs have a rapid cell cycle and an abbreviated G phase (Becker
et al., ). Rapid cell cycle progression in hESCs has been shown to be tied to
pluripotency, and slowing down the cell cycle by lengthening G through inhibi-
tion of Cdk causes hESCs to diﬀerentiate (Filipczyk et al., , Neganova et al.,
). Moreover, some of the canonical pluripotency proteins, such as Nanog,

have been directly implicated in regulating the cell cycle of hESCs. Nanog over-
expression was found to shorten the transition time between G and S phase by
directly binding to the regulatory regions of Cdk andCdcA (Zhang et al., ).
Given how closely connected the pluripotency and cell cycle networks are, it is pos-
sible that priming and pluripotency are linked via cell cycle machinery.
Mitochondrial morphology itself could be a factor in determining priming. It
has long been known that mitochondria can exist in a fused tubular state or a
fragmented state, and they can convert between these states through ﬁssion and
fusion processes (Bereiter-Hahn and Voth, , Lewis and Lewis, ). More
recent work has demonstrated that these dynamical changes are coordinated with
cellular processes, such as cell proliferation and diﬀerentiation (Mitra, ).
For instance, in somatic cells, mitochondria reach a fused state during the G-S
transition, which is associated with downregulation of Drp, a mitochondrial
ﬁssion-promoting GTPase (Mitra et al., ). Reduced Drp leads to eleva-
tion of cyclin E, promoting S phase entry and proliferation (Mitra et al., ).
However, despite their high proliferative capacity, hESCs are known to have
mitochondria that are fragmented, morphologically immature, and deﬁcient at
oxidative phosphorylation (Facucho-Oliveira and St. John, , Prigione et al.,
), suggesting that hESCs’ relatively rapid G-S transition might be diﬀeren-
tially regulated. Indeed, as hESCs diﬀerentiate, they not only undergo cell cycle
elongation but also develop more connected, complex, and metabolically active
mitochondria (Prigione et al., , Varum et al., ). Mitochondrial dynamics
may play a role in reprogramming as well; blocking ﬁssion using a Drp inhibitor
leads to a decrease in reprogramming eﬃciency of over , suggesting that

Figure 4.1 (following page): Proximity to the apoptotic threshold depends on
a combination of factors that diﬀer between hESCs and diﬀerentiated cells.
hESCs (left) and diﬀerentiated cells (right) are represented as hot air balloons ﬂoating
over lava (death). In this analogy, the size of the balloon envelope is the length of
the cell cycle; a longer G1 phase in diﬀerentiated cells allows them to ﬂoat higher,
conferring protection from death. The burners that generate hot air for the balloons
are represented by the mitochondria; fused mitochondria in diﬀerentiated cells provide
better propulsion (shown as a larger ﬂame) than fragmented mitochondria associated
with hESCs. Finally, pro-apoptotic proteins are shown as sand bags that weigh the
balloon down, and anti-apoptotic proteins are portrayed as scissors. In hESCs the
sand bags outnumber the scissors, while in diﬀerentiated cells the scissors are able
to cut oﬀ more of the sand bags. Summed together, the hESC balloon is in greater
danger of sinking toward death than the diﬀerentiated cell balloon.

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mitochondrial ﬁssion may be a critical feature of pluripotency (Vazquez-Martin
et al., ). Moreover, it has been suggested that mitochondrial connectivity
might have protective eﬀects on cell survival, and conversely, conditions of mito-
chondrial fragmentation could facilitate apoptosis (Karbowski and Youle, ).
us, the uniquemitochondrial morphology associated with the pluripotent state
could have both direct and indirect (via cell cycle) impact on priming. Deciphering
the interactions between the various players in these networks continues to be a
challenge, and most likely will require further studies looking at multiple systems
and the interconnections between them in the same cell.
. DNA      
Adult tissues have reserves of multipotent stem cells, which perform important
roles in homeostasis and recovery after injury. In general, adult stem cells tend
to be more resistant to damage than hESCs, though direct comparisons are diﬃ-
cult to make in human tissues. Many adult stem cell experiments have been per-
formed inmice, where adult stem cell populations can be isolated and sorted using
established label-retaining protocols. In severalmouse tissues, themost primitive
stem cells are relatively more resistant to damage. For instance, in comparison to
more committed progenitors, puriﬁed hematopoietic stem cells (HSCs) are resis-
tant to ionizing radiation (Mohrin et al., ). Similarly, mammary stem cells
(MaSCs) show resistance to X-ray-induced apoptosis, in contrast to progenitor
cells from mammospheres (Insinga et al., ). Skin is very sensitive to ioniz-
ing radiation, but in human epidermis slow-cycling keratinocyte stem cells (KSCs)
undergo post-damage cell death to a lesser extent than their direct progeny, the
keratinocyte progenitors (Rachidi et al., ). Conversely, candidate stem cells

toward the base of the small intestinal crypt aremore sensitive to irradiation than
small intestine progenitors higher up in the crypt (Qiu et al., ).
Variation in sensitivity to DNA damage among adult stem cells can be at-
tributed to at least three underlying causes. One factor could be the duration of
p activation, which was recently shown to aﬀect cellular outcomes in cancer
cells (Purvis et al., ). Diﬀerential p dynamics might also play a role in
cell fate decisions of stem cells in tissues in which p is induced. Indeed, hair
follicle bulge stem cells exhibit transient p activation after ionizing radiation
and are more resistant to cell death, compared with other cells of the epidermis
(Sotiropoulou et al., ). Long-term reconstituting HSCs are resistant to X-ray
irradiation and show a greatly attenuated p response (Insinga et al., ).
Interestingly, though short-term reconstituting HSCs do upregulate p, they are
also radioresistant, perhaps because p is activated to a lesser extent than in the
more sensitive committed progenitor cells (Insinga et al., ). A second poten-
tial cause for the variation in sensitivity is diﬀerential mitochondrial priming as
was discussed in the previous section, including disparities in the expression of
pro-apoptotic or anti-apoptotic proteins. For instance, due to their higher levels of
Bcl-, colon stem cells tend to bemore resistant to irradiation than small intestine
stem cells (Merritt et al., ), which may explain the higher frequency of colon
cancers compared with cancers of the small intestine. A third possible reason for
variation in sensitivity is cell cycle duration. An important diﬀerence between
hESCs and their adult counterparts is that in normal conditions many adult stem
cells do not cycle rapidly but instead are largely quiescent, resting in the G phase
of the cell cycle. Hence, while hESCs exhibit rapid cell cycle progression and have
high sensitivity to DNA damage, slower cycling in tissue-speciﬁc stem cells may

contribute to increased resistance to damage. Variation in sensitivity among
stem cells from diﬀerent tissues correlates with this trend. As aforementioned,
slow-cycling HSCs and KSCs are relatively resistant after irradiation. Actively
cycling stem cells from the small intestine, however, undergo apoptosis after even
low doses of irradiation. us quiescence appears to have a protective eﬀect on
stem cell survival.
Damage sensitivity also depends on the balances between competing signaling
pathways, such as DNA repair versus apoptosis. Which mode of damage response
is dominant in various tissues is still incompletely understood. Moreover, dif-
ferent cell types employ diverse DNA repair pathways, complicating our ability
to understand and predict how each system will respond to DNA damage (Blan-
pain et al., ). For instance, the relatively resistant, quiescent stem cells that
repair DNA after damage enter the cell cycle in G and hence use the error-prone
non-homologous end joining pathway. Consistently, studies have shown that qui-
escent stem cells accumulate DNA damage with age and their function becomes
progressively limited (Rossi et al., ). us cell cycle and DNA repair are in-
terlinked factors that aﬀect the decision between sensitivity and resistance, with
subsequent eﬀects that are compounded during aging.
. C     
Cancer cells tend to have higher rates of cell proliferation. If a relationship
between faster proliferation and greater radiosensitivity is reliable, it could po-
tentially be exploited for therapeutic purposes. In a recent study, BH proﬁling
was applied to predict the eﬀects of chemotherapy in patients with acute myeloid
leukemia (AML) (Vo et al., ). Mitochondrial priming was a determinant

of response to chemotherapy – the leukemia cells that were more primed were
the cells more likely to respond. Normal HSCs were less primed than the AML
myeloblasts of patients cured by chemotherapy. In AML patients who had re-
sponded poorly to chemotherapy, the myeloblasts were even less primed than
the HSCs, showing that the relative priming of HSCs and leukemia cells charac-
terized a boundary in clinical outcome. Moreover, BH proﬁling demonstrated
that the AMLmyeloblasts tended to depend on Bcl- for survival, while the HSCs
were selectively more dependent onMcl-. Hence, combining chemotherapy with
the addition of Bcl--inhibiting drugs could potentially increase priming of the
leukemia cells, improving the eﬃcacy of the treatment.
Understanding how damage response pathways and intrinsic mitochondrial
priming interact is clearly important for predicting the sensitivity of diﬀerent
tissues and the overall function and health of organisms. Regulated by inter-
connected networks including p signaling, cell cycle, and priming, stem cells
must navigate the delicate balance between resistance and sensitivity. Resistance
puts stem cells at risk of accumulating mutations that might lead to cancer, while
sensitivity is important for genetic stability but may cause stem cell depletion,
compromising function and contributing to aging. e line between resistance
and sensitivity, as we have seen, is incompletely understood even in well-studied
somatic cancer cell lines. e more we learn about how diﬀerent cell types - from
stem cells to cancer cells - respond to stress and damage, the better able we will
be to predict these responses and potentially manipulate them for therapeutic
purposes.

. M 
is chapter is adapted from a publication in press:
Julia C. Liu, Paul H. Lerou, and Galit Lahav. How stem cells walk the ﬁne line
between resistance and sensitivity to DNA damage. Trends in Cell Biology, in press.

Life is pleasant. Death is peaceful. It’s the transition that’s
troublesome.
Isaac Asimov
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Appendix: a novel method to detect apoptosis
and cell cycle
A         , the
ability to accurately measure the degree of apoptosis in cell populations is essen-
tial. Moreover, apoptosis is a multi-stage process, so ideally cellular progression
through apoptosis should be detectable. Pinpointing cells in the early and late
stages of apoptosis would enable the inference of the timing of commitment to

cell death after a given injury or damage.
Many cytotoxic agents also have eﬀects on the cell cycle, and at higher con-
centrations can induce apoptosis. Dependent on the mechanism of drug action,
apoptosis will occur from the cell cycle position in which the drug arrests the cells
(Schimke et al., ). Some anti-cancer drugs, such as paclitaxel (taxol), exert
their eﬀects by inhibiting entry into or progression through mitosis and thus can
cause cells to die in G/M (Rieder andMaiato, ). Many DNA-damaging drugs
impair DNA replication, for instance by inhibiting topoisomerase I (camptothecin,
for instance (Liu et al., )) or topoisomerase II (etoposide and doxorubicin,
among others (Pommier et al., )). ese drugs tend to be most toxic in S
phase, during which new DNA is synthesized. Identifying from which phase of
the cell cycle damaged cells die is a step towards being able to manipulate the dose
or timing of drugs or drug combinations to induce death or prevent it. Hence, it
is useful to measure both cell cycle phase as well as apoptosis in a distribution of
cells.
. M   
ere are a variety of methods used to detect apoptosis using a large range of
markers, such as morphology changes, caspase activation markers, membrane al-
terations, and DNA fragmentation (Elmore, ). Each of thesemethods has ad-
vantages and disadvantages in terms of speciﬁcity, time consumption, and cost.
Some may detect diﬀerent stages of apoptosis and be more or less appropriate
for use in speciﬁc contexts. Because no one method is suﬃcient on its own to
unequivocally demonstrate cell death, a combination of complementary yet unre-
lated techniques should be used (Galluzzi et al., ).

e gold standard for identifying apoptosis remains transmission electron mi-
croscopy (TEM), which can be used to detect changes in cell physiology directly
(Robertson et al., ). e classiﬁcation of apoptotic cells by deﬁnition requires
certain morphological characterisitics, among which are nuclear fragmentation,
disorganization of organelles, intact cell membrane even late in disintegration,
blebbing, and apoptotic bodies. TEM is able to detect thesemorphological changes
accurately. However, it is also costly, time-consuming, and limited to small re-
gions, making it particularly unsuitable for high-throughput experiments. Fur-
thermore, TEM is not optimal for detecting cells in the earliest stages of apopto-
sis.
Annexin V staining is a common method to detect early and late apoptosis
(Koopman et al., ). During apoptosis, phosphatidylserine is transferred
from the inner leaﬂet of the plasma membrane to the outer membrane. is
exposure of phosphatidylserine to the outside surface serves as a signal for
phagocytosis and also allows it to be detected by Annexin V. A recombinant
phosphatidylserine-binding protein, Annexin V stains dying cells before the
membrane is completely permeabilized. Hence, it is often combined with a
live-cell-impermeant dye such as propidium iodide (PI) which only stains dead
cells. When used in this combination, the Annexin V-positive, PI-negative cells
are generally regarded as early apoptotic and Annexin V-positive, PI-positive cells
are thought to be late apoptotic. While widely used and accepted as an apoptosis
assay, Annexin V staining does not provide information about cell cycle stage.
e TUNEL (Terminal dUTP Nick End-Labeling) method detects apoptosis
based on DNA fragmentation (Gavrieli et al., , Kressel and Groscurth, ).
is assay uses terminal deoxynucleotidyl transferase (TdT) to enzymatically la-

bel the DNA strand breaks generated by endonuclease cleavage during apoptosis.
TdT adds labeled dUTP to the ’-end of DNA fragments; the UTP can be labeled
with a variety of probes such as biotin or BrdU. Once incorporated into DNA, the
label can be detected with antibodies or other binding molecules. In some appli-
cations, these antibodies can be ﬂuorescent, so as to be detectable by microscopy
or ﬂow cytometry. When used in conjunction with a DNA-labeling dye such as
PI or DAPI (’,-diamidino--phenylindole), TUNEL can visualize the cell cycle
stage of the population of cells, including live and apoptotic cells. Hence, it is a
standard method to demonstrate correlation of induction of apoptosis with cell
cycle phase. However, it requires ﬁxation of the cells and incubation with the TdT
enzyme and whichever antibody is used to detect the labeled DNA ends, as well
as various washing steps between the incubations.
Antibodies against active caspases, such as cleaved caspase , and caspase cleav-
age products, including cleaved PARP, are also popular for detecting apoptosis.
Caspase activation and/or cleaved substrates can be detected in a variety of ways,
including immunoblotting and immunohistochemistry. In the same manner as
the TUNEL assay, when used for ﬂow cytometry, antibodies against cleaved cas-
pases or cleaved PARP can be combined with a DNA-labeling dye to concurrently
assess cell cycle stage and apoptosis.
. A        -

YOPRO- was identiﬁed as a live-cell-impermeant nuclear dye speciﬁc for apop-
totic cells (Idziorek et al., ). It is excluded from healthy cells and accurately
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Figure 5.1: Camptothecin induces S phase arrest and apoptosis in EL-4 cells.
(A) EL-4 cells were treated with : µ camptothecin for 8 hours, then collected
for the DCV/YOPRO ﬂow cytometry assay. Stages of apoptosis are demarcated by
incorporation of YOPRO, while cell cycle is measured by DCV (G1 and G2 peaks are
indicated).
stains the fraction of the population with morphological features of apoptosis,
such as nuclear shrinkage and fragmentation. Because it is used without perme-
abilization, a ﬁxation step is not required and the protocol becomes substantially
easier and more robust. Cells can be stained quickly, without ﬁxation, in media,
though prompt staining and analysis after the desired treatment are necessary.
YOPRO- or its counterpart YOPRO- (hereafter YOPRO) can be combined with
a live cell DNA stain such as Hoechst to simultaneously extract information about
cell cycle phase. For applications using ﬂow cytometers, in which laser sources
that excite Hoechst are rare, Vybrant DyeCycle Violet (DCV) can be substituted
for Hoechst (Telford, ). Like Hoechst, DCV is a cell-permeable DNA binding
dye with a similar structure to Hoechst. After binding DNA, DCV emits ﬂuores-
cence that is proportional toDNAmass, allowing for cell cycle analysis. Combined,
DCV and YOPRO can help determine after a given treatment whether cells arrest
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Figure 5.2: Camptothecin induces S/G2 arrest and apoptosis in 293T cells.
(A) 293T cells were treated with : µ camptothecin for 24 hours, then collected
for the DCV/YOPRO ﬂow cytometry assay. (B) Histogram of DCV distribution
of untreated cells (left) and overlay of the distributions of untreated (pink) and
camptothecin-treated (blue) cells (right).
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Figure 5.3: TUNEL conﬁrms camptothecin-induced S/G2 arrest and apop-
tosis. (A) 293T cells were treated as in (Figure 5.2), then ﬁxed for the Apo-BrdU
TUNEL assay. (B) Histogram of DAPI distribution of untreated cells (left) and over-
lay of the distributions of untreated (pink) and camptothecin-treated (blue) cells
(right).

and in what cell cycle stage, and from which stage they undergo apoptosis. We
developed an assay we term DCV/YOPRO for use in ﬂow cytometry.
We tested the DCV/YOPRO protocol on EL- mouse T lymphocyte cells, a lym-
phoma suspension cell line. In response to treatment with camptothecin, these
cells undergo apoptosis after arresting in S phase of the cell cycle (Johnson et al.,
). YOPRO staining appears to distinguish three classes of cells: low YOPRO
staining indicates live healthy cells, medium YOPRO staining marks cells in the
process of apoptosis, and high YOPRO staining is reserved for cells in the late
stages of apoptosis, where DNA fragmentation (lower DCV staining) becomes
common (Figure .).
e DCV/YOPRO assay can be used on not only suspension cells but also
trypsinized adherent cells. Human embryonic kidney (HEK) T cells also arrest
after camptothecin treatment and a small fraction of cells die (Figure .A,B).e
arrest can be clearly seen by a histogram along theDCV axis, which reports the cell
cycle proﬁle of the population (Figure .B). To compare our results to a known
apoptosis assay, we performed TUNEL using the Apo-BrdU kit (Life Technolo-
gies). Similarly to the DCV/YOPRO assay, apoptosis (in this case BrdU staining) is
on the y-axis and cell cycle (in this case DAPI) is on the x-axis (Figure .A,B). e
agreement between the two assays is fairly good, though YOPRO detects more
late-stage apoptotic cells. e diﬀerences are potentially due to the diﬀerent mor-
phological changes used as marks of apoptosis: while YOPRO detects membrane
changes, TUNEL reports DNA fragmentation, which is thought to be a later stage
of apoptosis. us, TUNEL may have better resolution of nearly dead cells but
miss some earlier events in apoptosis.
e DCV/YOPRO assay can potentially also be used to assess diﬀerences in
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Figure 5.4: Aphidicolin induces S-phase arrest and apoptosis in 293T cells.
(A) 293T cells were treated with  µg/ml aphidicolin for 24 hours, then collected for
the DCV/YOPRO ﬂow cytometry assay. (B) Histogram of DCV of untreated cells
(left) and overlay of untreated (pink) and aphidicolin-treated (blue) cells (right).
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Figure 5.5: Cisplatin induces S/G2 arrest and apoptosis in HCT116 cells.
HCT116 cells were treated with : µ cisplatin and at the indicated times after
damage were collected for the DCV/YOPRO assay.
responses to various drugs. For instance, T cells treated with aphidicolin, an
inhibitor of DNA polymerases and  and hence a blocker of replicative DNA syn-
thesis, also arrest in S-phasewith someS-phase-speciﬁc apoptosis (Figure .A,B).
Distinct from camptothecin-induced arrest, aphidicolin-induced arrest is more
speciﬁc to early S-phase (Figure .B). e DCV/YOPRO assay can potentially
be scaled up to be suited for high-throughput analyses of the eﬀects of diﬀerent
drugs at diﬀerent doses and timescales, on the same cell line or across diﬀerent

cell lines.
e DCV/YOPRO assay can also be used to analyze arrest and apoptosis with
more temporal depth for a particular cell line or treatment. As discussed in
Chapter , cisplatin treatment at its IC dose causes half of the population of
HCT cells to undergo apoptosis while the other half senesce. Performing the
DCV/YOPRO assay on cisplatin-treated HCT reveals cells in the early stages
of apoptosis at  hours and late-stage apoptotic cells comprising about half the
population by  hours (Figure .), in close agreement with the microscopy data
shown in Chapter . is ﬂow cytometry method allows further characterization
of divergent cell fate decisions in populations due to its ability to easily measure
large populations but at single cell resolution.
. M DCV/YOPRO     

Human embryonic stem cells (hESCs), as discussed in Chapter , are exquisitely
sensitive to DNA damage. ey exhibit spontaneous apoptosis in culture, as is
observed in the untreated condition. After treatment with the radiomimetic
DNA-damaging drug neocarzinostatin (NCS), hESCs undergo cell death which
has been previously characterized as apoptosis (Filion et al., , Grandela et al.,
, Liu et al., , Qin et al., ). e DCV/YOPRO assay conﬁrms that un-
diﬀerentiated hESCs undergo rapid apoptosis after damage is induced with NCS
(Figure .A). Additionally, this assay reveals that damage-induced apoptosis of
hESCs occurs fairly evenly from all stages in the cell cycle, without signiﬁcant
arrest.
When the DCV/YOPRO assay was performed on hESCs that had been diﬀeren-
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Figure 5.6: Undiﬀerentiated cells undergo apoptosis after damage while diﬀer-
entiated cells exclude DCV. (A) Undiﬀerentiated cells were treated with 200 ng/ml
of NCS and at the indicated times after damage were collected for the DCV/YOPRO
assay. (B) Cells diﬀerentiated with RA for 4 days were concurrently treated with NCS
as in (A) and collected for the DCV/YOPRO assay.
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Figure 5.7: Inhibition of ABCG2 transport by fumitremorgin restores the nor-
mal cell cycle proﬁle of diﬀerentiated cells. As in Figure 5.6, RA-diﬀerentiated
cells were treated with 200 ng/ml of NCS and at the indicated times after damage
were collected for DCV/YOPRO assay; fumitremorgin was added 30 minutes before
collection.
tiated with retinoic acid (RA) for  days, then damaged with the same NCS treat-
ment, we observed a peculiar shift of all cells leftward toward the hypodiploid re-
gion of the axis, even in the untreated control (Figure .B). As almost all cells
were alive, given the low amount of cell death even after NCS treatment, we sus-
pected that this phenomenon occurred not as a result of DNA fragmentation (in
the absence of apoptosis) but instead arose from a problem with DCV staining in
this cell type.
We hypothesized that one reason that DCV incorporation and DNA binding
would be impaired is if the cells were to pump out the dye. Certain cell types are
known to express transporters that can pump out a wide range of drugs and other
small molecules. For instance, the ATP-binding cassette (ABC) transporters com-
prise several subfamilies of eﬄux pumps with broad drug speciﬁcity. While lit-
tle is known about the function of these transporters in vivo (van de Wetering
and Sapthu, , Vlaming et al., ), increased expression or activity of such

multidrug eﬄux pumps are known to contribute to multidrug resistance in can-
cer cells by lowering intracellular drug concentrations (Gottesman et al., ).
Chemotherapy drugs known to be aﬀected include vinblastine, vincristine, dox-
orubicin, daunorubicin, actinomycin-D, and paclitaxel (Ambudkar et al., ).
Moreover, some cell types have been identiﬁed based on exclusion of the
DNA-binding Hoechst dye. e ﬁrst cells so described, named side population
(SP) cells because of their low Hoechst proﬁle on ﬂow cytometry, were a sub-
set of adult mouse bone marrow with enriched hematopoietic stem cells (HSCs)
(Goodell et al., ). Cells from multiple other tissues and cancer cell types that
exclude Hoechst and its close relative DCV have since been shown to correspond
to adult stem cell and tumor-initiating cancer cell populations (Mathew et al.,
, Telford, , Telford et al., ). Eﬄux of Hoechst was attributed to the
ABC family of membrane transporters, and speciﬁcally shown to be dependent on
ABCG (breast cancer resistance protein, BCRP) (Scharenberg et al., , Zhou
et al., ), initially identiﬁed in multidrug-resistant breast cancer cells. We
therefore investigated whether impaired DCV incorporation in RA-diﬀerentiated
cells was due to ABCG-mediated eﬄux of DCV.
To demonstrate that RA-diﬀerentiated cells indeed excluded DCV due to the
activity of ABCG, we employed fumitremorgin, a potent and speciﬁc inhibitor
of ABCG (Mathew et al., ). Addition of fumitremorgin to diﬀerentiated
cell samples restored the normal DCV/YOPRO proﬁle of diﬀerentiated cells (Fig-
ure .. is suggested that ABCG was active in diﬀerentiated cells. We there-
fore assessed the expression of ABCG in both undiﬀerentiated and diﬀerentiated
cells. A recent study had shown that hESCs have very low ABCG protein lev-
els (Padmanabhan et al., ), but RA could potentially diﬀerentiate hESCs into
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Figure 5.8: Diﬀerentiated cells express the ABCG2 pump. (A). Negative con-
trols for ABCG2 staining, including unstained cells (red) and isotype control (orange),
for undiﬀerentiated (dashed lines) and diﬀerentiated cells (solid lines). (B). Undiﬀer-
entiated cells stained with ABCG2 (cyan) compared to unstained and isotype control
conditions. (C). ABCG2 staining in undiﬀerentiated and diﬀerentiated cells. Horizon-
tal line in all plots is an estimation of ABCG2-positive staining.
an intermediate state that might correspond to an adult stem or progenitor cell.
Staining with an anti-ABCGmonoclonal antibody that speciﬁcally recognizes an
extracellular epitope of ABCG revealed little expression in undiﬀerentiated cells
and a drastic increase in ABCG expression in diﬀerentiated cells (Figure .). We
thereby determined that DCV staining was incomplete in RA-diﬀerentiated cells
due to ABCG pump activity; however, the DCV/YOPRO assay can still be used
when ABCG is inhibited.
. D
ere are many techniques to detect various features of apoptosis, all with some
advantages and some limitations. If we wish to additionally extract information
about the cell cycle stage of the living and dying cells, there are fewer options.

We developed the DCV/YOPRO assay to address the need for a method to con-
currently assess cell cycle stage and apoptosis that can be quickly and easily per-
formed. DCV/YOPRO is a simple yet powerful tool that because of its ease of use
can be scaled up to sample across diﬀerent drugs, dosages, and cell lines as well as
provide thorough temporal resolution of a few conditions. It is important, how-
ever, to conﬁrm the analysis of apoptosis with at least one independent exper-
imental approach which ideally should rely on a diﬀerent parameter associated
with apoptosis other than membrane permeability (Galluzzi et al., ).
. M  
Cell culture: EL- and T cells were grown in DMEM with  fetal calf serum
(FCS),  U/ml penicillin,  µg/ml streptomycin, and  ng/ml fungizone.
HCT cells were grown in McCoy’s media with the same supplements. hESCS
(H line) culture and retinoic acid (RA) diﬀerentiation were performed as de-
scribed in Chapter .
Antibodies and reagents: Unlabeled ABCG antibody (clone D) and the cor-
responding mouse IgG kappa isotype control were obtained from eBioscience
Inc. Secondary antibody labeling was performed with anti-mouse Alexa- (Life
Technologies). Reagents used are as follows: camptothecin (Sigma), aphidicolin
(Santa Cruz Biotechnologies), cisplatin (Sigma), neocarzinostatin (Sigma), and fu-
mitremorgin C (Enzo Life Technologies).
Flow cytometry: Cells were dissociated when needed with trypsin or Accutase
(Stemcell Technologies) and centrifuged. For the DCV/YOPRO assay, cells were
resuspended in media at a concentration of    cells/ml. Vybrant DyeCycle
Violet (Life Technologies) was added to a ﬁnal concentration of - µM, and cells

were incubated for minutes at C. YOPRO- (Life Technologies)was added to a
ﬁnal concentration of .-. µM, and cells were incubated for minutes at room
temperature, then analyzed on a BD LSRII ﬂow cytometer and data were analyzed
in FlowJo. YOPROwas detected in the DsRed channel, and DyeCycle Violet in the
Paciﬁc Blue channel. e TUNEL assay was performed with the Apo-BrdU TUNEL
kit (Life Technologies), according to the manufacturer’s suggested protocol.
. M 
Author contributions: Julia C. Liu and Jodene K. Moore conducted the experi-
ments and performed the analysis. Characterization of hESCs and diﬀerentiated
cells with DCV/YOPRO and ABCG staining was performed by Julia C. Liu. Julia
C. Liu wrote this chapter.
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